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Vitamin B6 deficiency as measured by plasma concentrations of pyridoxal 5` phosphate 
(P5P), the active form of vitamin B6, has been reported in several organ transplant recipients. 
The highest incidence of vitamin B6 deficiency has been observed in small bowel transplant 
recipients. The current study evaluated the potential mechanisms (increased degradation of P5P 
due to higher levels of alkaline phosphatases; or decreased formation of P5P due to decreased 
expression and activity of pyridoxal kinase) that may contribute to such observations. Higher 
plasma concentrations of alkaline phosphatases, decreased plasma albumin concentrations and 
higher amount of excretion of 4-pyridoxic acid in the urine of small bowel transplant patients 
supported the role of increased degradation of P5P. Of the various medications used by 
transplant patients that were tested using computation approach, pantoprazole, trimethoprim, 
acyclovir, valganciclovir and mycophenolic acid appeared to be most likely to inhibit pyridoxal 
kinase. Tacrolimus, the primary immunosuppressive drug used in most transplant recipients had 
limited impact on pyridoxal kinase expression and activity. A pro-inflammatory cytokine, TNF-
α, decreased the expression and activity of pyridoxal kinase in primary cultures of human 
hepatocytes. The higher plasma concentrations of TNF-α observed in small bowel transplant 
patients is consistent with a decreased activity of pyridoxal kinase in the liver of these patients, 
and supported decreased formation of P5P also as a contributor to the observed vitamin B6 
deficiency. Additional studies in an animal model where an organ that was not directly involved 
in the absorption, formation or degradation of vitamin B6 (a composite allograft tissue 
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transplantation), showed a significant reduction in the expression of pyridoxal kinase in the liver. 
This suggested that the process of organ transplantation (immune activation and inflammation) 
itself led to vitamin B6 deficiency. Our studies indicate that vitamin B6 deficiency is expected in 
all transplant recipients; however, the magnitude of deficiency is likely to be affected by the 
immunogenicity of the transplanted organ and the immune status of the patient. Given the 
potential effect of vitamin B6 deficiency (neurotoxicity), and the low cost of vitamin B6, it is 
prudent to consider supplementation of all transplant patients with vitamin B6. 
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1.0  INTRODUCTION 
Organ transplantation has become the treatment of choice for many patients with end 
stage organ failure. Organs such as kidney, liver, lung, heart, pancreas, and small intestine are 
routinely transplanted and organ transplantation has significantly improved the over all patient 
survival. However, despite the relative success of this treatment option in terms of decreased 
morbidity and mortality, post-transplant care has continues to be a challenge.  These care plans 
include the use of immunosuppressant medications, and prophylactic medications (antifungals, 
antivirals, etc.), in addition to the medications administered for existing other co morbidities 
(diabetes, hypertension, hyperlipidemia, etc.). Besides these treatment protocols, the functional 
recovery and the nutritional status are critically important determinants of the overall success of 
transplantation. For example, clinical nutritional autonomy is usually achieved shortly after small 
bowel transplantation in most cases. However, the full functional recovery of the transplanted 
small bowel has not yet been completely evaluated. In a recent study by Matarese et al., a full 
scale screening of serum concentrations of micronutrients in intestinal transplant patients 
revealed a significant deficiency in vitamin B6. The study identified specific risk factors and 
established a clinically useful repletion protocol for small bowel transplant patients.   
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Normally, vitamin B6 deficiency is rare and it does not usually progress towards a 
clinical deficiency that necessitates an intervention. This is due to the fact that vitamin B6 is 
widely available through diet and is also synthesized by the colonic micro flora. Various 
explanations have been offered to account for the decrease in plasma P5P concentrations in  
majority of small bowel transplant patients, including reduced dietary intake and/or poor 
intestinal absorption of vitamin B-6, increased degradation by alkaline phosphatase (ALP), 
altered metabolism of vitamin B-6, increased urinary excretion of 4-pyridoxic acid (4-PA) and 
drug-nutrient interactions. Deficiency of vitamin B6 following small bowel/multivisceral 
transplantation may also be due to increased metabolic demand due to trauma and inflammation. 
The increasing metabolic demand due to surgery or inflammation can not adequately explain the 
development and progression of vitamin B6 deficiency several months after transplantation. 
Similarly, the fact that Vitamin B6 is mainly absorbed by passive process and that the deficiency 
is reported in various other solid organ transplant recipients makes poor intestinal absorption a 
less likely explanation for the observed vitamin B6 deficiency in transplant patients. On the other 
hand, increased degradation of pyridoxal 5` phosphate by enzymes like alkaline phosphatase into 
pyridoxal, which  is ultimately catabolized to urinary 4-pyridoxic acid or the impact of  drugs 
taken by transplant patients on pyridoxal kinase, the enzyme responsible for formation of 
pyridoxal 5` phosphate, has not yet been investigated. 
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1.1 VITAMIN B6 
Vitamin B6 is one of the essential vitamins that the human body is not able to synthesize.  
It exists in various chemical forms that differ from each other in the substitutions of different 
groups at position 4. Pyridoxine carries a hydroxyl group, pyridoxal an aldehyde and 
pyridoxamine an amine group at this location [1]. Vitamin B6 is a water soluble vitamin that is 
passively absorbed from the upper part of the small intestine by simple diffusion [2]. Vitamin B6 
is obtained from two different sources: in dietary source, from which it is mainly absorbed in the 
small intestine passively, and bacterial source, where the vitamin is synthesized by the micro 
flora in the large intestine. A carrier mediated active transport was suggested to be involved in 
the uptake of micro flora synthesized vitamin B6 [3]. The intestinal absorption of vitamin B6 
may be lower in patients with malabsorption or following gastric resection.  The main storage 
site for vitamin B6 is the liver with lesser amounts being stored in the muscle and brain.  
The active form of vitamin B6, pyridoxal 5’ phosphate (P5P) is involved as a cofactor in 
more than 140 distinct enzymatic reactions in the body. The enzymes involved include: 
oxidoreductases, lyases, transferases, hydrolases and isomerases. These P5P dependent enzymes 
are involved in many physiological processes such as amino acid metabolism, fatty acid 
metabolism, degradation of glycogen, and hemoglobin formation. In addition, P5P plays an 
important protective role as an antioxidant [1].  
All forms of Vitamin B6 are converted to the active form pyridoxal -5-phosphate (P5P) 
by pyridoxal kinase. This enzyme is expressed in many tissues such as brain, red blood cells and 
liver; however the majority of plasma P5P is formed in the liver. Pyridoxal 5’ phosphate in the 
circulation is strongly associated with albumin and hemoglobin. The unbound form will be 
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dephosphorylated by phosphatases to pyridoxal, which will be further oxidized by the aldehyde 
oxidase to the ultimate degradation product 4-Pyridoxic acid (4-PA). The metabolism of vitamin 
B6 in laboratory animals like rats is similar to that reported in humans [4]. 
Several drugs have been identified as inhibitors of pyridoxal kinase and thereby vitamin 
B6 metabolism. According to the mechanism of inhibition, these drugs are classified into three 
groups: 
1. The first group of drugs, which includes isoniazid, dopamine, cycloserine and 
thiamphenicol glycinate, forms covalent complexes with pyridoxal or P5P, via Schiff’s 
base formation. These complexes will directly inhibit pyridoxal kinase.  
2. The second group of drugs includes theophylline and progabide, which are true inhibitors 
of pyridoxal kinase that compete with the known substrates such as pyridoxal or 
pyridoxamine, however, without any complex formation.  
3. The third group of drugs includes levodopa, D-penicillamine, and muzolimine, also forms 
a complex with either pyridoxal or P5P, however, these complexes have no inhibitory 
effect on pyridoxal kinase, but they rather prevent the substrate from interacting with 
pyridoxal kinase [5].  
Vitamin B6 has been used for several non-nutritional indications as well. These 
indications include, but are not limited to, depression, impaired glucose tolerance and diabetes 
mellitus, morning sickness, and carpal tunnel syndrome [6]. The therapeutic doses vary with the 
indication, and typically involve high doses (50 -200 mg) of vitamin B6.  
Several indicators of vitamin B6 status have been developed and utilized clinically. These 
indicators include direct measures such as plasma or erythrocyte vitamin concentration, or 
urinary 4-pyridoxic acid; and functional measures such as stimulation or activation of 
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erythrocyte aspartate aminotransferase (α-EAST) and alanine aminotransferase (α-EALT) by 
pyridoxal 5` phosphate. Less frequently used tests are the methionine load test, where an increase 
in methionine metabolites such as homocysteine and cystathionine indicate the vitamin B6 
status.  In another test, the tryptophan load test, the urinary xanthurenic acid (XA) is measured. 
The following table summarizes all of these tests and their respective reference values [7].  
 
 
 
Table 1. Parameters for assessment of vitamin B6 status and reference values  
Parameter  Reference value 
Direct Plasma pyridoxal 5` phosphate (P5P) >30 nmol/L  
 Total vitamin B6 >40 nmol/L 
 Urinary 4-pyridoxic acid excretion (4-PA) >3µmol/day 
 Urinary total vitamin B6 >0.5 µmol/day 
Indirect α-EAST <1.8 (80%) 
 α-EALT <1.25 (25%) 
 XA excretion (2 g L-Tryptophan) <65µmol/day 
 Cystathionine excretion (3 g L-methionine) <350 µmol/day 
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1.2 VITAMIN B6 DEFICIENCY 
Vitamin B6 deficiency is not uncommon and has been reported in different pathological 
conditions such as cirrhosis, malabsorption, uremia, hyperthyroidism and congestive heart 
failure. Morris and colleagues in a large epidemiological study evaluated the prevalence of 
vitamin B6 deficiency in the U.S population. The results suggested that about 11% of those who 
took a daily supplement, and 25 % of those who did not take any supplement have a plasma P5P 
level of less than 20 nmol /L.  The study concluded that the recommended daily allowance of 
vitamin B6 of 2 mg/day may be inadequate in certain vulnerable patient populations [8]. 
However, biochemical deficiency does not always lead to clinical consequences where 
symptomatic manifestations occur. Actually, clinical deficiency is rare, and once detected can be 
easily corrected by supplementation. In many cases, vitamin B6 deficiency is overlooked 
especially in the absence of clinical signs and symptoms. Symptoms of vitamin B6 deficiency 
due to either disease state or concomitant medications have been observed and they usually 
manifest as neurological problems [6]. The most common manifestations of vitamin B6 
deficiency include hematological, immunological, cognitive, neurological and cardiovascular 
abnormalities. Vitamin B6 deficiency has been associated with impaired immune function that is 
characterized by decreased lymphocytes and interleukin-2 (IL-2) production. Some studies have 
suggested a significant inverse correlation between serum pyridoxal 5` phosphate and some types 
of cancer such as colorectal, pancreatic, gastric, oral and pharyngeal, lung, prostate and breast. 
The role of vitamin B6 in neurocognitive functions is well established, especially in seizures and 
different neuropathies. Finally, vitamin B6 deficiency has also been associated with some 
cardiovascular abnormalities like atherosclerosis and myocardial infarction [7]. 
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Vitamin B6 deficiency has been reported in different solid organ transplant patients. 
Vitamin B6 deficiency has been reported in almost all intestinal and multivisceral transplant 
patients. This was the first report that highlights such deficiency in this population. In a 1- year 
prospective study of intestinal and multivisceral transplant recipients (isolated intestine (n=19) 
combined liver intestine (n=3), multivisceral (n=8)), P5P deficiency was observed in 96% of the 
recipients with a median onset of 30 days after transplantation. Of this group 41 % were 
receiving parenteral nutrition, 41% were receiving enteral feeding, and 18% had complete 
nutritional autonomy. The overall cumulative risk was 24% at 25 days, 59% at 30 days, 79% at 
45 days and 90% at 90 days. In these patients, baseline P5P levels ranged from 9.7 – 301.5 
nmol/L [9]. 
Vitamin B6 deficiency has been reported in as much as 60 % of the liver transplant 
patients. Bosy-Westphal and coworkers observed lower P5P levels in a subgroup of orthotopic 
liver transplant patients (OLT) (n=54), compared to a control group (n=25). The P5P plasma 
levels in the control group were 64 (±54) nmol/L, with 12% of them with less than 20 nmol/L, 
while the P5P levels in the OLT group were 30 (±49) nmol/L, with 61% of them with less than 
20 nmol/L. The levels were lower in OLT with normal serum creatinine, when compared with 
the OLT patients with elevated creatinine. The P5P levels were 17 (±13) nmol/L, with 67% less 
than 20 nmol/L and 58 (±78) nmol/L, with 56% less than 20 nmol/L, respectively. Furthermore, 
P5P levels were inversely correlated with alkaline phosphatase levels in serum after OLT (r=-
0.32, P<0.05). As P5P is almost 90% bound to plasma proteins, less albumin in liver transplant 
patients might lead to increased free fraction and correspondingly increased degradation of the 
free P5P by alkaline phosphatase [10]. 
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Vitamin B6 deficiency has also been reported in more than 50% of kidney transplant 
patients. In 1983, Lacour et al. reported that in 116 non-uremic kidney transplant patients the 
mean plasma P5P was 33.8±3.5 nmol/L. In 65% of these patients the levels were < 20 nmol/L. 
The immunosuppressant regimen used in these patients was azathioprine and corticosteroid [13]. 
Furthermore, Plessis and coworkers compared P5P levels in two groups of renal transplant 
patients (less than 28 months post-transplant and more than 28 months post-transplant). The 
vitamin B6 levels were below normal in 56% in the first group and 59% in the second group 
[14]. 
Vitamin B6 deficiency has been reported in more than 20% of heart transplant patients. 
In one hundred and sixty patients who underwent orthtopic heart transplant the P5P level was 
measured along with other vitamins and biomarkers. The mean P5P concentration was ranged 
from 66 to 72 nmol/L. A deficiency was seen in 21% of recipients with cardiovascular 
complication and 9% in recipients without complications. Furthermore, survival in those with 
vitamin B6 deficiency was significantly lower than in those without a deficiency [15]. Similar 
results of lower P5P levels were reported in another group of 189 cardiac transplant patients 
when compared to healthy controls (40±25 vs. 84±77 nmol/L, respectively) [16]. 
The level of alkaline phosphatase has been correlated with P5P levels in plasma (normal 
level 20- 140 IU/L). The levels of P5P are markedly increased (21- fold) in clinical cases of 
hypophosphatemia (low alkaline phosphatase levels) [17]. On the contrary, elevated levels of 
alkaline phosphatase (like in cases of inflammation, trauma etc.) will lead to lower P5P levels. 
Increased levels of alkaline phosphatase, which plays an important role in degradation of 
P5P, have been reported in different transplant patients. Hranjec and colleagues reported a case 
of high alkaline phosphatase in a liver transplant patient and attributed the increase in alkaline 
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phosphatase to Epstein - Barr virus and the immunosuppressant regimen used that included 
tacrolimus, mycophenolate mofetil and corticosteroid [18]. Similarly, three renal transplant 
patients have been reported to have elevated alkaline phosphatase levels for idiopathic reasons. 
The immunosuppressive regimen in all the three cases included tacrolimus [19]. These 
observations led to the suggestion of a potential role of tacrolimus as a cause of the observed P5P 
deficiency. 
The success of solid organ transplantation is strongly related to advances in 
immunosuppressive therapy. The major issues with early transplantation were high failure rates 
and frequent acute rejections. However with new immunosuppressive agents like cyclosporine 
and tacrolimus, the rejection rates currently are much lower. After a few decades of use, the 
concentration has been shifted from just preventing the acute rejection to balancing that with less 
adverse effects. One of many adverse effects observed after organ transplantation is the poor 
nutritional status of the transplant patients. This is important as many of the patients undergoing 
transplantation are nutritionally vulnerable [15]. For example, the transplant candidates 
especially for small bowel transplantation will be usually receiving parenteral nutrition (PN) as 
their primary nutritional support. 
The immunosuppressive medications used in different organ transplant populations 
reporting decreased P5P levels are varied. Tacrolimus was the primary immunosuppressant used 
in all the small bowel transplant patients. The immunosuppressive therapy regimens used in liver 
transplantation included cyclosporine, tacrolimus, azathioprine and mycophenolate mofetil. In 
Kidney transplantation, the immunosuppressant regimen was cyclosporine, azathioprine and 
corticosteroids. Finally, the heart transplant patients’ immunosuppressive regimen included 
azathioprine, cyclosporine and prednisone 
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The proposed mechanisms for vitamin B6 deficiency in transplant populations include 
the increased metabolic demand that will exhaust the vitamin B6 sources, inadequate intake, 
abnormal metabolism (decreased formation), or drug interaction [9]. Finally, a metabolic 
abnormality is most likely to occur, either decreased formation (inhibition of pyridoxal kinase) or 
increased degradation (increased alkaline phosphatase). This last mechanism has never been 
tested in this patient population. 
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1.3 SMALL BOWEL TRANSPLANTATION 
1.3.1 Small bowel transplantation 
Given the highest incidence of vitamin B6 deficiency in small bowel transplant patient, 
we will now focus on small bowel transplant patients. The small bowel known as small intestine 
is the major site of absorption of drugs and nutrients. The small bowel is about six meters in 
length that extends from the stomach to the colon and is composed of three distinct regions: 
duodenum, jejunum and the ileum [20]. The structure of these segments varies significantly, 
along with a change in the pH from being slightly acidic in the beginning to almost neutral 
towards the end. In addition, the stomach contents will be mixed with bile and pancreatic 
enzymes in the upper part of the small bowel [21]. Drug and nutrient absorption mainly takes 
place throughout the intestine via different mechanisms that range from passive to active 
pathways. In addition, drugs and nutrients can concurrently be metabolized and or transported 
(uptake or efflux). Small bowel transplantation is considered the only therapeutic option for 
patients with intestinal failure [22].  
Intestinal failure is a condition where the absorptive capacity of the intestine is seriously 
compromised. This can be attributed to many factors that can range from congenital defect to 
disease induced malfunction or injury [23]. One of the common diseases that can precipitate such 
a condition is chronic irritable syndrome, known as Crohn`s disease. Less common causes may 
include trauma, short gut syndrome, thrombosis and intestinal obstruction [24] Most of the 
patients with intestinal failure become dependent on parenteral nutrition (PN); however, the only 
ultimate therapeutic option for intestinal failure is small bowel transplantation [25]. The type of 
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small bowel transplantation performed varies according to patient’s requirements and can be a 
standalone procedure or combined with other organs such as liver [26]. While intestinal failure is 
the main indication for small bowel transplantation, it has been performed with other organs for 
extended list of indications that include intestinal failure with cirrhosis, complete portal 
mesenteric thrombosis, slow- growing central abdominal tumors, intestinal pseudo obstruction, 
and frozen abdomen [27]. Transplantation may in essence include small bowel alone, liver-small 
intestine, the whole gastro-enteric system with liver and pancreas, and the new emerging 
procedure that includes stomach-duodenum-pancreas and intestine without the liver [28]. 
The function of the transplanted organ in terms of absorption, immunity and motility is of 
importance post transplantation. Absorption capacity is usually inferred from achieving the 
nutritional autonomy, normal height/age ratio, and body mass index. The immunity is monitored 
by intraepithelial lymphocyte as the first line of host immunity, while the motility is expected to 
recover slowly with re-innervation [29]. The immunological complications after intestinal 
transplantation is a major challenge and several trials have suggested the use anti-tumor necrosis 
factor α (anti-TNF-α) to prevent or treat rejection [30, 31]. Due to the complexity of the surgery 
and the high immunogenicity of the transplanted organs, there is a higher incidence of severe 
rejection and re-transplantation [32]. In addition, the donor specific antibody is also a unique 
challenge in small bowel transplants that may require the use of additional therapies against anti-
donor antibodies [33].  Several immune monitoring techniques are utilized similar to other organ 
transplantation; however a few additional monitoring techniques such as flow cytometric mixed 
leukocyte responses, measurement of fecal calprotectin and single-nucleotide polymorphisms 
associated with inflammatory bowel diseases are also utilized [34]. 
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1.3.2 Medication use after small bowel transplantation 
Many small bowel transplant recipients like other solid organ transplant patients receive 
multiple medications as early as a few days prior to the surgery and will continue on most of 
these medications for the rest of their lives. The primary medication used in transplant patients is 
usually tacrolimus, which is the main immunosuppressant that is targeted to a therapeutic 
concentration range of 10-15 ng/ml.  
In addition to the immunosuppressant tacrolimus, many other medications are commonly 
prescribed to small bowel transplant patients. The following table summarizes different drugs 
that are commonly prescribed in this patient population. 
Table 2. Medications commonly prescribed to small bowel transplant patients 
Immunosuppressant Pneumocystis Carnii  
Prophylaxis 
Cytomegalovirus  
Prophylaxis 
Supplements Anti-fungal 
Prophylaxis 
Others 
Tacrolimus Sulfamethoxazole - 
Trimethoprim 
Adefovir Vitamin D3 Itraconazole psychotropics 
Cyclosporine Dapsone Acyclovir Vitamin B12 Fluconazole Anti-
hypertensive 
Hydrocortisone Atovaquone Valganciclovir Folic Acid Voriconazole Antibiotics 
Prednisone   Biotin Nystatin Antihistamines 
Azathioprine   Vitamin B2  Pain Med 
Sirolimus   Niacinamide  PPI’s 
   Vitamin B6   
   Vitamin A   
   Vitamin B1    
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 1.4 TACROLIMUS 
Since Tacrolimus is used in all small bowel transplant patients, we will now focus on a 
discussion of this medication. Tacrolimus is the immunosuppressant of choice in all solid organ 
transplantations like liver, kidney and small bowel. Known as FK-506, it is a 23-memebered 
macrolide lactone, which is isolated from the fermentation broth of Streptomyces tskubaensis. 
Tacrolimus inhibits lymphocyte proliferation by binding to FK-binding proteins 
(immunophilins), which in turn inhibits the activity of calcineurin (a serine threonine 
phosphatase).  Calcineurin will be unable to dephosphorylate the nuclear factor of activated T 
cells (NFATc), resulting in suppression of IL-2 transcription. 
 
Figure 1. Structure of Tacrolimus  
 
Tacrolimus has a narrow therapeutic index and requires routine monitoring of its 
concentration in whole blood to decrease the probability of rejection and minimize toxicity.  The 
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desired trough blood concentration of tacrolimus depends on the organ transplanted and other co-
administered immunosuppressive drugs and is usually maintained between 8-15 ng/ml. The main 
adverse effects associated with tacrolimus are neurotoxicity, nephrotoxicity, and electrolyte 
disturbances like hypomagnesaemia and hyperkalemia [35].  
Tacrolimus pharmacokinetics and drug interactions have been extensively studied. 
Briefly, the bioavailability from orally administered tacrolimus ranges from 5- 67%, with an 
average of 29% in liver, kidney, or intestinal transplant patients. This low bioavailability has 
been attributed to gut metabolism (CYP3A) and gut efflux (p-glycoprotein) [36]. Tacrolimus 
distributes between blood cells and plasma with a mean blood to plasma ratio 15:1. Clinically, 
whole blood tacrolimus concentrations are usually measured instead of plasma concentrations. In 
blood, tacrolimus is associated with erythrocytes, while in plasma it is associated with alpha1-
acid glycoprotein (67-91% bound) and to albumin (69% bound) [36]. Finally, tacrolimus is 
mainly cleared from the body by CYP3A4 enzymes into at least nine different metabolites that 
are primarily secreted in the bile. Tacrolimus is subjected to several drug interactions, and many 
of these interactions are either CYP3A based inhibition (azoles), CYP3A based induction 
(rifampicin), or P-glycoprotein transporter based interactions. Other types of drug interactions 
that are not CYP3A or P-glycoprotein based have not yet been investigated [35]. 
There were no reports of interaction in the literature between tacrolimus and vitamin B6. 
The documented vitamin B6 deficiencies in most patients on tacrolimus give us a basis for our 
hypothesis of a potential effect of tacrolimus on vitamin B6. Tacrolimus may lead to vitamin B6 
deficiency by either decreasing the formation of P5P, by inhibiting the enzyme pyridoxal kinase 
and/or increasing the degradation of P5P by elevating the levels of alkaline phosphatase. and 
consequently their physiological functions.  
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1.5 VITAMINS STATUS FOLLOWING TRANSPLANTATION 
1.5.1 Introduction 
Vitamins are required by the body to carry out several vital functions. They are usually 
needed in small quantities. There have been many reported serious complications that were due 
to specific vitamin deficiencies. These complications can range from anemias, neuropathy, and 
osteoporosis to well-defined disease states like scurvy and beri-beri.  Alterations in vitamin 
status after solid organ transplantation have also been reported in the literature.  These have been 
primarily deficiencies that include both fat soluble vitamins (A, D, E, and K), as well as water 
soluble vitamins (B1, B2, B6, B3, and B12). The extent and severity of deficiency varies 
considerably depending on the type of organ transplanted and the perioperative nutritional 
support used. Often, vitamin deficiencies are associated with organ dysfunction and are normally 
corrected once a new allograft is received. The purpose of this review is to evaluate the vitamin 
status following solid organ transplantation. 
Altered fat soluble vitamins status has been reported after kidney and liver 
transplantations.  Vitamins status may be affected after transplantation due to inadequate intake 
or supplementation, disturbed activation by different organ systems, or by immunosuppressive 
medications used. For Example, renal transplant recipients have a higher prevalence of vitamin 
D deficiency as the kidney is the site of activation of vitamin D into 1:25-hydroxyvitamin D 
(37). The prevalence of deficiency and insufficiency in this population is approximately 70-80% 
[38]. The deficiency has been associated with secondary hyperthyroidism and hypocalcaemia 
[39]. Although, the prevalence of deficiency is high regardless of transplant status (recent or 
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long-term), it has been reported to occur in most of the African American kidney recipients [40]. 
Interestingly, a recent study reported severe vitamin D deficiency among heart and liver 
transplant recipients despite vitamin supplementation [41]. Likewise, the plasma concentrations 
of vitamin A, a fat-soluble vitamin, which is predominantly stored and metabolized in liver, was 
lower post liver transplant patients [42]. Studies reported that both vitamin A and vitamin E 
levels are lower in patients with cirrhosis before transplantation [43, 44]. Increased levels of both 
fat soluble vitamins (vitamin A and vitamin E) have been reported in adult cystic fibrosis 
patients after lung transplantation [45]. The exact requirements of supplementation for fat 
soluble vitamins may differ depending on the type of organ transplanted.  While vitamin K is 
important for the biosynthesis of procoagulant serum protein factors in the liver [46], vitamin E 
may have beneficial effects in heart transplantation. 
Similarly, deficiency of water soluble vitamins has been reported in patients undergoing 
different organ transplantation. Vitamin B6 deficiency was significant following intestinal 
transplantation and to lesser extent in kidney, liver and cardiac transplantation [9, 12]. Similarly, 
acute folic acid deficiency was observed after bone marrow transplantation [47]. However, there 
are reports of normal levels of B-group vitamins after renal transplantation [48]. 
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 Table 3. Summary of vitamin deficiencies following solid organ transplantation 
Vitamin Organ 
  
Vitamin A liver 
Vitamin D 
Vitamin E 
Kidney, liver 
Liver, Lung 
Vitamin K  liver 
Vitamin B6 Small bowel, heart, 
liver, kidney 
Vitamin B12 heart 
Thiamine Kidney, liver 
        
1.5.2 Fat soluble vitamins 
The fat soluble vitamins include vitamin A, D, K, and E. Vitamin D was among the most 
studied vitamin, especially in kidney transplant patients. Vitamin concentrations in various solid 
organ transplantations will be summarized below.  
Vitamin A 
Vitamin A and its metabolites are important for cellular growth and play an important 
role in differentiation of various epithelial and immune cells. It is very important for growth and 
vision as well as for its antioxidant protective role. The naturally occurring ester form of vitamin 
A is usually hydrolyzed to retinol that is taken up by the intestinal mucosa, re-esterified back, 
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coupled with chylomicrons, and finally released via the thoracic duct into the circulation. The 
remnants of the carrier – containing most of the ester form- are taken by the liver and stored after 
hydrolysis as retinol. The serum level of vitamin A is maintained through homeostatic regulation 
from the liver stores. Retinol is bound to retinol-binding protein (RBP) before being released and 
further coupled to transthyretin (TTR) to minimize renal elimination. In the cells, retinol is 
bound to cellular RBP, oxidized to retinoic acid, or re-esterified again. The ester form is stored in 
different tissues in addition to liver, where 50-80% of the body store is maintained [49]. 
Cytochrome P450 26 hydroxylation as well as glucuronidation are involved in this process.  
Vitamin A status following transplantation 
Vitamin A deficiency, defined as plasma retinol levels of less than 1μM, has been 
reported in patients with end-stage liver disease awaiting transplantation.  Both plasma retinol 
(normal level 1.6 – 2.3 μM) and serum retinol binding protein RBP (normal level 1.4 – 2.9 μM) 
were lower in pre liver transplant patients (100 and 95% of the patients, respectively), than 
normal subjects.  Similarly, 82% (n=77) of pretransplant patients with primary sclerosing 
cholangitis had serum vitamin A levels that were below the normal range [50]. Ukleja and co-
workers reported significantly lower levels of serum and hepatic vitamin A levels as well as the 
RBP in fifty patients with cirrhosis compared to matching control subjects [44]. Dark adaptation 
that resulted from vitamin A deficiency in patients waiting for liver transplantation was 
improved by intramuscular vitamin A treatment [51]. 
Following liver transplantation, a beneficial effect on restoring the nutritional status of 
patient with cystic fibrosis was noted. Both vitamin A and vitamin E levels increased (P<0.05) 
subsequent to transplantation [52]. In addition, a case report of a patient with severe visual field 
restriction that failed vitamin A supplementation showed improvement following liver 
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transplantation [53]. However, a case of night blindness secondary to vitamin A deficiency has 
been reported after transplantation also. This patient likely developed a biliary stricture as a 
complication of the transplantation procedure [54]. Serum vitamin A and retinol binding protein 
were significantly reduced in the kidney transplant patients during the immediate post-transplant 
period, but consistently increased several years after transplantation [55].  
  
Vitamin D 
Vitamin D that exists in two different forms - vitamin D2 (known as ergocalciferol) and 
Vitamin D3 (known as cholecalciferol), is best known for its beneficial effects on bone health. It 
is known to be involved in the intestinal absorption of minerals like calcium, iron, magnesium, 
and phosphate. Vitamin D is normally absorbed from the intestine into the circulation where it 
binds to vitamin D-binding protein (DBP). The two forms of vitamin D (D2 and D3) need 
successive hydroxylation in the liver and kidney to form active 1, 25-dihydroxyvitamin D.  It is 
transported to liver, where it is hydroxylated to 25-hydroxy vitamin D, by microsomal CYP450 
(CYP2R1) and/or mitochondrial CYP450 (CYP27A1). In kidneys, 25-hydroxyvitamin D3-1α-
hydroxylase (CYP27B) will ultimately add another hydroxyl group at position 1 to convert 25-
hydroxy vitamin D to the dihydroxy active form. The normal vitamin D status, usually measured 
by 25-hydroxy vitamin D levels, is considered to be at least than 50 nmol/L or 20 ng/ml. New 
assays are able to measure the 1, 25 di-hydroxy vitamin D metabolite and the normal range is 
between 16 and 60 pg/ml [46, 56]. 
Vitamin D status following transplantation 
Vitamin D deficiency has been reported in transplant candidates with congestive heart 
failure, end-stage pulmonary disease, liver failure and most commonly chronic kidney diseases 
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[44]. Transplantation unfortunately will not restore vitamin D status regardless of the 
transplanted organ. Estimates of prevalence of vitamin D deficiency following transplantation 
were variable according to patient populations, type of transplanted organ, and are also 
dependent on assay used to measure 25-hydroxy metabolite. The vitamin D insufficiency is not 
uncommon and it is estimated that 26-33% of transplant patients developed severe deficiency 
[41]. Low vitamin D levels have been suggested to be utilized in kidney transplant patients as a 
predictor of worsening of graft function and increasing proteinuria [37]. About 40-50% of 
patients were vitamin D deficient post-renal transplantation and almost 90% of patients were 
vitamin D deficient after liver and/or heart transplantation.  The etiology of vitamin D deficiency 
varies and can range from malnutrition, lack of sun exposure, steroid therapy, alterations in 
metabolism by the liver [38, 39, and 41] 
 
Vitamin E 
Vitamin E, known as α-tocopherol, is poorly absorbed through intestinal tract and 
transported via lipoproteins and chylomicrons to liver and other tissues. Vitamin E is 
metabolized by cytochrome P450’s then conjugated and excreted in urine or bile. Hepatic 
CYP4F2 is primarily involved in metabolizing vitamin E; in addition CYP3A may also be 
involved. Vitamin E deficiency is defined as α-tocopherol plasma concentration of less than 12 
μmol/L [46]. 
Vitamin E status following transplantation 
Vitamin E deficiency had been reported in patients with alcohol-related liver disease, 
viral hepatitis, and hepatocellular carcinoma [44]. Forty three percent of pretransplant patients 
with primary sclerosing cholangitis had vitamin E levels below normal [50]. The levels of 
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vitamin E were increased significantly (p<0.05) in cystic fibrosis patients following liver 
transplantation when compared with non-transplanted patients [52]. Similar findings with lung 
transplant recipients have also been reported [45].  
Vitamin K 
Vitamin K, found mainly in green plants as a known phytonadione, is absorbed from the 
intestine via the lymphatic system. Tissue carboxylation as well as hepatic reductases has a role 
in conversion of vitamin K to the active epoxide form. The deficiency is rare; however it has 
serious consequences .The normal plasma concentration is estimated to be 1.0 nmol/L (0.45 
ng/ml) [46] 
Vitamin K has a crucial role in the biosynthesis of procoagulant serum protein factors in 
the liver [57]. Chronic liver diseases usually require vitamin K supplementation to restore 
hemostatic abnormalities [58]. Few studies have evaluated vitamin K status prior to 
transplantation as the deficiency can occur due to many different reasons. These reasons include: 
drug antagonism, liver dysfunction, inadequate intake and/or malabsorption. About 30% of 
children patients (8/26) pre-bone marrow transplantation had vitamin K deficiency [59]. 
Vitamin K status following transplantation 
Vitamin K deficiency after transplantation was reported in a series of case reports after 
kidney and combined kidney-pancreas transplantation. Four patients from a total of 146 
transplant patients developed vitamin K deficiency induced coagulopathy and bleeding 1-week 
after transplantation [60]. Hemostatic abnormalities associated with liver transplantation are 
rather inherently related to different surgical phase of the transplantation and no data is available 
about vitamin K status post liver transplantation [58]. 
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1.5.3 Water soluble vitamins 
Water soluble vitamins are less frequently evaluated and reported in the transplant 
literature. Only vitamin B1, B3, B6, and B12 levels have been reported in different solid organ 
transplant patients. Vitamins status of patients after solid organ transplantation will be 
summarized separately.  
Vitamin B6 
Vitamin B6, known as pyridoxine, is composed of three naturally occurring distinct 
chemical forms as free pyridoxamine, phosphorylated pyridoxal and pyridoxal.  Pyridoxamine 
and the other forms will be absorbed passively in the jejunum. The non-phosphorylated forms 
will cross into the circulation. Pyridoxal binds to albumin and erythrocytes where it will bind to 
hemoglobin.  The majority of the absorbed vitamin B6 in the unphosphorylated form is 
transported to liver by simple diffusion where metabolism by pyridoxal kinase into the active 
form pyridoxal-5 phosphate (P5P) takes place. The active form P5P is either released into plasma 
or is bound to Apo-enzymes. The P5P undergoes hydrolysis by non-specific alkaline 
phosphatase. Most excess pyridoxal in tissues will be oxidized to urinary 4-pyridoxic acid by 
liver and kidney [61]. The normal level of P5P is between 30-80 nmol/L and the total body 
storage is estimated to be about 167 mg.   
Vitamin B6 deficiency is not uncommon and has been reported in different pathological 
conditions in patients with alcoholism, cirrhosis, malabsorption, uremia, hyperthyroidism and 
congestive heart failure. Morris and colleagues in a large epidemiological study evaluated the 
prevalence of vitamin B6 deficiency in U.S population. The results suggested that about 11% 
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who took a daily supplement, and 25 % who did not take any supplement have a P5P level of 
less than 20 nmol /L [8].  
Vitamin B6 status following transplantation 
Recently, Matarese et al. reported a high incidence of vitamin B6 deficiency following 
small bowel and multivisceral transplantation ~96% [9]. Variable degrees of deficiencies have 
also been reported in liver transplant patients (60 %)  [10], renal transplant patients (50 %) [11] 
and, cardiac transplant patients (20 %) [12]. Vitamin B6 deficiency occurred in about 59% of 
renal transplant recipients after more than 28 months post transplantation [14]. In another study, 
vitamin B6 levels were lower in cardiac transplant patients than controls and the deficiency was 
seen in about 17.9 % of the transplant patients in comparison to 2.2 % in controls [16]. However, 
the mechanism of this deficiency has not been investigated so far. 
Vitamin B12 
Vitamin B12, known as cyanocobalamin- is actively absorbed through a highly specific 
mechanism in the ileum that depends on intrinsic factor and its receptors. The liver and the 
kidneys are the richest repositories of vitamin B12, also known as cobalamin, in the body. 
Vitamin B12 is metabolically active as coenzyme B12 and as methylcobalamin. Three soluble 
B12 binding proteins (intrinsic factor, transcobalamin, and haptocorrin) are known to be 
involved in the uptake and transport of cobalamins in human [61].  A significant amount of 
vitamin B12 is secreted in the bile; however, about 70% is normally re-absorbed. The normal 
serum cobalamin value ranges between 200 and 250 ng/L. The deficiency usually is due to 
inadequate intake, gastrointestinal malabsorption, or metabolic disorders such as nitrous oxide 
toxicity [46]. In addition to serum cobalamin levels, serum methylmalonic acid concentrations 
have been utilized as an index of tissue cobalamin status [62]. 
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Vitamin B12 status following transplantation 
Gupta et al. studied 189 orthotropic cardiac transplant recipients and found that 
cobalamin deficiency was present in 4.3% of their patients and in 5.3 % of controls [16]. Vitamin 
B12 deficiency was not significantly different between heart transplant patients with and without 
cardiovascular complications and furthermore, vitamin B12 concentrations failed to predict 
complications or death [12].  Similarly, in renal transplant patients (n=55) there were no 
differences in the mean vitamin B12 levels compared to the matched control group (n=32) [48].  
 Vitamin B1  
Vitamin B1 is a water soluble B-vitamin known as Thiamine. Best known for its 
neurological effect as it is involved in neurotransmitter synthesis and in the treatment of 
alcoholism. Tissue thiamine deficiency was suggested as a potential cause of delayed graft 
function after kidney transplantation, which was improved by thiamine supplementation to the 
donors (63). Thiamine supplementation improved signs and symptoms of a liver transplant 
patient who developed hemorrhagic Wernicke’s encephalopathy [64]. Wernicke’s 
encephalopathy is a metabolic disorder that is mainly caused by thiamine deficiency and 
frequently associated with chronic alcoholism and some forms of malnutrition or malabsorption. 
Few cases of this disorder were similarly reported after allogenic peripheral blood stem cell 
transplantation [65, 66].  
 
Vitamin B3  
Vitamin B3, known as Niacin, is obtained from the diet from in the form of tryptophan, 
nicotinic acid and nicotinamide. All utilized for synthesis of NAD that mediates many 
biochemical redox reactions. Pellagra, which results from a deficiency of niacin, can lead to 
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severe consequences and eventually death. Nicotinic acid is converted in the intestine into 
nicotinamide, which is the predominant form in the circulation. Many cellular transporters were 
identified to transfer both chemical forms into various cells. However, nicotineamide is also the 
degradation product of the pyridine nucleotides [67]. There were no reported deficiency in niacin 
following transplantation, however it is very likely as niacin metabolism is largely dependent on 
vitamin B6 as an essential co-factor. Further studies are essential in this area. 
1.5.4 Conclusion 
Deficiencies in various vitamins have been reported following different solid organ 
transplantations. The underlying causes have been attributed to organ specific function 
associated with that specific vitamin. Dietary intake, changes in metabolism and other 
biochemical processes attributed to transplantation or immunosuppression were stated as the 
reason for deficiencies observed without adequate evidence. Depending on the organ, 
transplantation requires variable levels of immune suppression that may affect the overall 
wellbeing and the long-term rehabilitation of the recipient. Different transplantation patients may 
experience variable degrees of deficiencies in different vitamins. Renal transplant patients are 
more likely to develop vitamin D deficiency, while liver transplants are more prone to develop 
vitamin A, D, E and K deficiency. The mechanisms underlying each deficiency also can be 
variable and unforeseen in many cases. This review draws attention to further mechanistic 
analysis of these deficiencies for better understanding of the nutritional status of organ transplant 
patients. Of all the transplant patients evaluated so far, small bowel transplantation appears to be 
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the major population with high incidence of deficiency in one of the water soluble vitamins, the 
vitamin B6. 
1.6 HYPOTHESIS AND SPECIFIC AIMS 
Vitamin B6 deficiency appears to be common in all transplant patients. The magnitude of 
deficiency appears to vary from one organ transplant group to another, with the highest incidence 
being reported in small bowel transplant patients. Different mechanisms have been suggested to 
be responsible for such an observation. The active form of vitamin B6 is pyridoxal 5` phosphate 
that is formed in the liver by the enzyme pyridoxal kinase. The active form is predominantly 
bound to albumin and red blood cells. Decreased plasma pyridoxal 5` phosphate in transplant 
patients may be due to inhibition of enzymes involved in its formation by concurrent drugs or 
elevated inflammatory markers like cytokines, that are typically increased in organ transplant 
patients. Decreased plasma pyridoxal 5` phosphate in transplant patients may be due to increased 
degradation by plasma alkaline phosphatase, decreased plasma protein binding of pyridoxal 5` 
phosphate due to lower concentration of albumin in transplant patients that may lead to increased 
free fraction and increased degradation, drugs administered, or surgery and elevated 
inflammatory markers that might alter the metabolism of various vitamins.  
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 Figure 2. Biochemical processes involved in the metabolism of vitamin B6 vitamers 
   1:Pyridoxal kinase , 2: Oxidase, 3: alkaline phosphatase, 4: aldehyde oxidase 
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 Hypothesis and Predictions: 
Hypothesis 1: Plasma pyridoxal 5` phosphate concentrations will be decreased in 
transplant patients due to increased degradation mediated by elevated plasma alkaline 
phosphatase concentrations. 
Prediction: Alkaline phosphatase levels will be increased after transplantation and there 
will be higher urinary excretion of the degradation product, 4-pyridoxic acid in patients 
urine. Urine samples will be collected from small bowel transplant patients for 12 hours 
period for measurement of 4-pyridoxic acid. The total amount of 4PA excreted will be 
compared between small bowel transplant patients and normal healthy control subjects.   
 
Hypothesis 2: Free fraction of pyridoxal 5` phosphate will be increased due to lower 
concentration of albumin in patients or due to displacement by other drugs that are also 
bound to albumin (Tacrolimus) and this will lead to increased clearance of P5P to 4-PA 
Prediction: Albumin levels will be lower after small bowel transplantation. Tacrolimus 
will increase free fraction of P5P in plasma. Albumin levels will be compared between 
small bowel transplant patients and normal healthy subjects.  
 
Hypothesis 3: Plasma pyridoxal 5` phosphate concentration will be decreased in 
transplant patients due to decreased expression of pyridoxal kinase and/or direct 
inhibition of pyridoxal kinase involved in its formation by concurrent drugs administered. 
Prediction: The medications used in transplant patients will decrease the expression and 
or directly inhibit the formation of P5P. A computational approach will be used to 
 29 
 
identify the probable drug interactions of the most commonly used drugs in small bowel 
transplantation with pyridoxal kinase. The computer program will design the 
conformational structure of pyridoxal enzyme and identified the binding pockets. The 
chemical structure of selected medications will be screened for their virtual spatial fitness 
to these corresponding pockets. The docking score of each chemical structure will be 
recorded and compared to the docking scores of various known inhibitors that will be 
used to validate the correctness of the spatial configuration of the enzyme. 
 
Hypothesis 4: Plasma P5P concentrations will be lower in transplant patients due to 
decreased expression or inhibition of pyridoxal kinase by increased cytokine levels. 
Prediction: The following cytokines will be elevated (IL-6, IL-8, IL-10, and TNF-α) 
during the early post-transplant study session.  Both IL-6 and TNF- α level will remain 
elevated at the later post-transplant session. TNF- α will significantly decrease the 
expression and activity of pyridoxal kinase in primary cultures of human hepatocytes.  
 
Hypothesis 5: The process of transplantation itself will elevate inflammatory markers and 
will decrease the expression and activity of pyridoxal kinase. 
Prediction: Transplantation of an organ that is not involved in the absorption and 
metabolism of vitamin B6 will alter the liver pyridoxal kinase metabolic capacity.  
A composite allograft tissue transplant animal model will be employed. The liver extracts 
will be tested for pyridoxal kinase activity using pyridoxal as probe substrate and the 
expression of pyridoxal kinase in liver tissues will be evaluated using RT-PCR.  
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AIMS 
Aim1: To analyze of the causes of vitamin B6 deficiency following small bowel 
transplantation in patients (4-PA, Alkaline Phosphatase, Albumin) (Chapter 3). 
This study will quantitate the degradation product 4-pyridoxic acid (4-PA) in small bowel 
transplant patients at two different times after transplantation. The amounts of urinary 4-
PA will be measured using HPLC.  Plasma Alkaline phosphatase and serum albumin will 
be measured as part of the clinical care and the results will be collected from the patient 
charts. We predict increased amount of 4-PA in small bowel transplant patients in 
comparison to healthy subjects which is due to higher alkaline phosphatase levels. 
 
Aim 2: To evaluate plasma cytokines levels after transplantation (Chapter 3) 
Plasma cytokine levels will be measured at various time points after small bowel 
transplantation. The following cytokines will be measured (IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-12, INFγ, and TNF-α) at both the early and the later post-transplant study 
session. Each individual cytokine concentration will be compared with its concentration 
measured in healthy control subjects. 
 
Aim 3: To evaluate the activity of pyridoxal kinase in human liver extract and 
   human hepatocytes in culture in presence of tacrolimus and cytokines  
  (Chapter 4,5). 
The pyridoxal kinase activity will be measured in presence of different concentrations 
of tacrolimus in human liver extracts and hepatocytes with pyridoxal as the substrate 
and by measurement of pyridoxal 5`phosphate formed.  Pyridoxal kinase mRNA 
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expression in hepatocytes in presence of different concentrations of tacrolimus and 
selected panel of cytokines will also measured with RT-PCR. A supporting in silico 
computational approach will be utilized to identify possible inhibitors.  
Aim 4: To determine the effect of inflammation and transplant process on vitamin 
 B6 metabolism (Chapter 6). 
In order to obtain the highest impact of transplantation on the whole body system without 
involving an organ that is directly or indirectly involved in absorption or metabolism of 
vitamin B6, a composite allograft tissue model will be employed. Transplantation of the 
hind limb will be performed as follows: Iso graft (white - white), allograft (white – 
brown), and allograft that will receive tacrolimus (white - brown) and control groups. 
Different tissues and organs will be collected. The liver extracts will be tested for 
pyridoxal kinase activity using pyridoxal as probe substrate and the expression of 
pyridoxal kinase in liver tissues will be evaluated using RT-PCR.  
 Aim 5: To determine the effect of tacrolimus on serum protein binding (Chapter 5). 
Pyridoxal 5`Phosphate binding to serum albumin will evaluated in the presence of  
different tacrolimus concentration. Both Pyridoxal 5`phosphate and tacrolimus bind to 
serum albumin, so the degree of  displacement will be evaluated in vitro using 
ultrafiltration. 
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2.0  VITAMIN B6 METABOLITES ASSAY DVELOPMENT 
Abstract 
We present a simple and validated high performance liquid chromatographic method 
(HPLC) for measuring Vitamin B6 metabolite, 4-pyridoxic acid (4-PA) in human urine samples. 
Urine samples were treated with 6 % perchloric acid to precipitate any proteins. Separation of 
various components was achieved using (Symmetry® C18 250mm x 4.6 mm I’d (5µm) column 
(Waters Inc.). The mobile phase used was a mixture of methanol and 35 mM sodium phosphate 
buffer containing 2.5 mM sodium heptane polysulfonate at pH of 3.5 with 85% O-phosphoric acid. 
The retention time was 8.0 min for 4-pyridoxic acid.  UV detection at 302 nm for the analyte was 
linear in the concentration range from 0.0125 to 0.8 µM. The assay showed acceptable sensitivity 
and selectivity and was very reproducible. Correlation coefficient of linear fit curve for 4-
pyridoxic acid obtained from data was greater than 0.99.  The accuracy and precision data from 
back calculated calibration standards demonstrate suitability of the calibration method. 
Deviations from the nominal concentrations and CV values were from 1 to 16% and 3.8 to 
17.5% for all concentration levels, respectively. The mean intra- and inter-day accuracy and 
precision for the back calculated concentrations for quality control medium (QCM) (0.25µM) 
and   quality control high (QCH) (0.5 µM) samples were within 15% and for quality control low 
(QCL) (0.05 µM) samples were within 20%. The recovery from urine was (76% ± 0.2%) vs. 
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(104±0.8 %) from water for QCL and the recovery from urine was (88.0 ±0.8 %) vs (89.1 ±6.8 
%) from water for QCH. In conclusion, this method is stable, reproducible and has practical 
advantages such as ease and low cost over previously published methods for analysis of 4-PA in 
urine. 
2.1 VALIDATION OF AN HPLC-UV METHOD FOR ANALYSIS OF 4-PYRIDOXIC 
ACID IN HUMAN URINE 
2.1.1 Introduction 
Vitamin B6 is a water soluble vitamin that exists predominantly as pyridoxine. Vitamin 
B6 is converted by pyridoxal kinase to its active metabolite (P5P), which is involved in more 
than 140 biochemical reactions. Pyridoxal 5` phosphate is highly protein bound and is ultimately 
converted to inactive 4-pyridoxic acid that is excreted into urine.   
Different analytical methods are reported in the literature for the assay of vitamin B6 
metabolites in plasma and urine including spectrophotometry, fluorimetry, and HPLC. Several 
analytical methods utilized fluorimetric detection either directly or through chemical 
modification to improve sensitivity of detection. The methods included pre-column or post 
column derivatization [68-72]. One method utilized coulometric detection [73]. These methods 
were limited by the extra chemical step that either needs to occur before or after column 
separation. The sensitivity and accuracy of these methods were also not optimal.  The aim of this 
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work was to develop a validated, simple and reproducible method for the estimation of the major 
urinary metabolite of vitamin B6 in human urine. 
2.1.2 Materials and Methods 
2.1.3 Reagents 
4-pyridoxic acid (4-PA) was purchased from Sigma (St. Louis, MO, USA). Methanol, 
sodium heptane sulfonate, and orthophosphoric acid 85%, were purchased from Fluka. Sodium 
phosphate monobasic, sodium phosphate dibasic, animal charcoal and perchloric acid were 
purchased from Fischer. Reagent-grade water obtained from a Millipore Milli-Q system was used 
throughout the experiments. All other reagents were of analytical grade. 
2.1.4 Apparatus and chromatographic conditions 
The HPLC system consisted of a Waters 2695 separation module and Waters 2998 
photodiode array detector. A reverse-phase column Waters Symmetry® C18 250mm x 4.6 mm i.d 
(5µm) was used to separate the analytes, and the temperature of the column was held at 25°C. 
The gradient mobile phase consists of: methanol (20-80%) (phase A) and  35 mM sodium 
phosphate buffer (phase B) containing  2.5 mM ion-pairing agent sodium heptane polysulfonate 
that was adjusted to pH of 3.5 with 85% orthophosphoric acid. The buffer was sonicated, filtered 
and degassed prior to run. The flow-rate was 1 ml/min. Injection volume was 50µl. The detector 
was set at 302nm. Total run time was 10 minutes. 
 35 
 
2.1.5 Preparation of solutions 
Stock solution of 4-pyridoxic acid (1mM) was prepared by dissolving it in HPLC grade 
water. Stock solution was further diluted with charcoal pre-treated urine (to remove endogenous 4-
pyridoxic acid) to working standard solutions with concentrations ranging from 0.0125 µM to 0.8 
µM. All solutions were stored at -80◦C to simulate the storage conditions of the study samples and 
were found to be stable for at least 2 months. Quality control samples were prepared by separately 
weighing 4-PA and preparing the solutions as described earlier. 
Validation of the method was performed according to FDA guidelines [74]. Peak area 
detected at the retention times of the analyte of interest was measured. The linearity of the assay 
over a range of 4-pyridoxic acid concentrations 0.0125 -0.8 µM was assessed. The recovery for 
each concentration was calculated against the theoretical concentration. Inter- and intra- day 
precision, accuracy and recovery were also calculated for all standards as well as three quality 
control standards (quality control low (QCL), quality control medium (QCM), quality control high 
(QCH)). Bench-top stability for quality control samples after 1hr and 4hrs at room temperature as 
well as auto sampler stability after 24 hours was also performed. Long term stability after 3 months 
storage and after several freeze-thaw cycles were also carried out. Finally, dilution analysis at 1:1, 
1:2, and 1:4 folds were performed for quality control sample for accuracy and precision as well as 
recovery.   
The accuracy and precision of the analytical method were evaluated by analysing quality 
control samples at three concentration levels (QCH 0.5 µM, QCM 0.25 µM, QCL 0.05 µM). Six 
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of both QCH and QCM level and twelve of QCL level were analysed daily for three runs. The 
calculated mean concentration was used to express accuracy (% deviation): 
% deviation = (Calculated concentration value – Reference concentration)/Reference 
Concentration X 100 
Means, standard deviations and coefficients of variation were calculated from QC values 
and used to estimate the intra- and inter- day precision: 
% Coefficient of Variation = (Standard deviation of calculated Concentrations / Mean of 
calculated concentrations) X 100 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Preparation of standard and controls 
Urine samples obtained from six different sources were treated with activated charcoal 
then analyzed according to the procedure previously described, in order to evaluate method 
specificity. Treatment with activated charcoal will remove all interference and to make sure there 
are no endogenous chemicals with retention times similar to 4-pyridoxic acid. These samples 
confirmed the appropriateness of using this method to prepare blank urine samples without any 
interference of endogenous 4-pyridoxic acid. A representative chromatogram of 4-pyridoxic acid 
in urine is shown in Figure 3. The retention time of 4-pyridoxic acid was 9 minutes in the run 
shown in figure. 
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Figure 3. Chromatogram of 4-pyridoxic acid (4-PA) in urine (0.8 µM) 
 
2.2.2 Standard Curve  
Standard curve samples were analyzed in three separate runs. For each curve, the 
absolute peak areas of the analyte (4-pyridoxic Acid) were plotted against the nominal 
concentrations. Calibration curves were obtained for analyte over the concentration range 
of 0.0125 – 0.8 µM. The correlation coefficients (r) were greater than 0.99. The lowest 
standard on the calibration curve was identified as the lowest concentration where the 
analyte peak area is reproducible with a precision of 20% and accuracy of 80-120%. The 
lowest concentration should be within 20% deviation from the nominal concentration and 
the rest of standards should be within 15% from nominal concentration. At least four out of 
six non-zero standards met these acceptance criteria. 
 38 
 
The accuracy and precision were evaluated with quality control samples of known 
concentrations in urine. Three quality control samples (QC) that represent the whole 
concentration range were prepared as follows: QCL is within 3-times the lower limit of 
quantification (0.05 µM), QCM is near the middle of the calibration range (0.25 µM), and 
QCH is near the high end of the calibration range (0.5 µM). The concentrations of 
calibration and quality control standards are stated in Table 4. 
 
Table 4. Standards and quality control samples 
Calibration Standard/ Quality 
Control (QC) 
Concentration µM 
STD 1 0.0125 
STD 2 0.025 
STD 3 0.05 
STD 4 0.1 
STD 5 0.2 
STD6 0.4 
STD 7 0.8 
QCL 0.05 
QCM 0.25 
QCH 0.5 
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2.2.3 Linearity 
Matrix-based calibration standards, in the range of 0.0125-0.8 µM, were independently 
prepared and analysed, on three different days for inter- and intra-day variation. For each curve, 
the absolute peak areas of the analyte (4-pyridoxic acid) were plotted against the nominal 
concentrations. Correlation coefficient of linear fit curve for 4-pyridoxic acid obtained from data 
was greater than 0.99 (Figure 4).  
 
 
Figure 4. Calibration curve of 4-pyridoxic acid in urine  
 
The accuracy and precision data from back calculated calibration standards demonstrate 
suitability of the calibration method.  Deviations from the nominal concentrations and CV values 
were within <15% for all concentration levels, and <20% for the lowest concentration (0.0125 
µM). Recovery was also > 80% at all tested concentrations. The results are shown in Table 5. 
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Table 5. Calibration Curve standard Concentrations accuracy, precision, and recovery. 
Standard 
Concentration 
µM (n=6) 
Calculated 
Concentration 
µM 
SD CV% Deviation % Recovery % 
0.0125 0.012 0.002 17.4 -6.8 93.2 
0.025 0.022 0.94 13.4              -13.1 86.9 
0.05 0.050 0.003 5.1 -0.4 99.6 
0.1 0.097 0.003 3.0 -2.9 97.1 
0.2 0.194 0.002 1.2 -2.9 97.1 
0.4 0.384 0.004 1.1 -4.0 96.0 
0.8 0.765 0.012 1.5 -4.3 95.7 
 
 
The accuracy and precision of the analytical method were evaluated by analysing quality 
control samples at three concentration levels (QCH 0.5 µM, QCM 0.25 µM, QCL 0.05 µM). Six 
of both QCH and QCM level and twelve of QCL level were analysed daily for three runs. The 
obtained values for accuracy and precision were within FDA requirements. The mean inter- and 
intra-day accuracy and precision for the back calculated concentrations for QCM and QCH 
samples were within 15% and for QCL samples were within 20%. Inter-day precision, accuracy 
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and recovery values are shown in table 6 while the intra-day values for day 1-3 are shown in 
Tables 7,8, and 9, consequently. 
 
Table 6. Recovery, accuracy and inter-day precision, 4-Pyridoxic acid assay validation 
Theoretical 
concentration 
   (µM) (n=6) 
Calculated concentration 
       (µM±SD) 
Precision 
CV % 
Accuracy  
       Deviation % 
Recovery  
        %±SD 
0.0125 0.011±0.002              17.5 -16.1 83.7±4.3 
0.025 0.024±0.002 8.3 -5.2 94.8±6.8 
0.05 0.050±0.004 6.9 0.9 101.5±3.4 
0.1 0.095±0.005 5.4 -5.4 83.9±14.7 
0.2 0.201±0.008 4.0 0.4 94.8± 7.9 
0.4 0.433±0.037 8.6 8.2 100.9±7.0 
0.8 0.808±0.030 3.8 1.0 94.6±5.1 
QCL*  0.042±0.002 5.2 -16.3 100.4±4.0 
QCM  0.237±0.017 7.2 -4.9 108.2±9.3 
QCH 0.507±0.017 3.4 1.5 101.0±3.8 
*n=12 
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Table 7. Recovery, accuracy and intra-day precision day 1, 4-Pyridoxic acid assay validation 
Theoretical 
concentration 
   (µM) (n=6) 
Calculated 
concentration  
   (µM±SD) 
Precision 
   CV % 
Accuracy 
Deviation % 
Recovery  
     % 
0.0125 0.011±0.002 18.6 -10.2 89.8 
0.025 0.024±0.002 7.4 -4.3 95.7 
0.05 0.046±0.005 8.9 3.8 103.8 
0.1 0.097±0.002 1.6 -3.4 96.6 
0.2 0.208±0.01 4.6 4.1 104.1 
0.4 0.411±0.008 2.0 -17.9 102.7 
0.8 0.81±0.011 1.4 1.2 101.2 
QCL* 0.041±0.002 3.6 17.9 82.1 
QCM 0.230±0.023 10.0 -9.4 90.6 
QCH 0.522±0.023 4.4 4.5 104.5 
  *n=12 
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Table 8. Recovery, accuracy and intra-day precision day 2, 4-pyridoxic acid assay validation 
Theoretical 
concentration 
   (µM) (n=6) 
Calculated 
concentration  
   (µM±SD) 
Precision 
   CV % 
Accuracy 
      % 
Recovery  
     % 
0.0125 0.010±0.001 9.1 -21.7 80.0 
0.025 0.023±0.002 10.6 -8.1 92.0 
0.05 0.051±0.001 2.9 1.1 101.1 
0.1 0.094±0.005 5.4 -5.7 94.3 
0.2 0.194±0.003 1.3 -2.8 97.2 
0.4 0.413±0.003 0.8 3.2 103.2 
0.8 0.782±0.030 3.9 -2.3 97.7 
QCL* 0.040±0.001 3.6 -20.0 80.0 
QCM 0.243±0.005 2.1 -2.7 97.3 
QCH 0.501±0.006 1.2 2.1 100.3 
*n=12 
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Table 9. Recovery, accuracy and intra-day precision day 3, 4-pyridoxic acid assay validation 
Theoretical 
concentration 
   (µM) (n=6) 
Calculated 
concentration  
   (µM±SD) 
Precision 
   CV % 
Accuracy 
      % 
Recovery  
     % 
0.0125 0.011±0.001 11.2 -13.7 86.3 
0.025 0.023±0.001 3.0 -7.1 92.9 
0.05 0.045±0.001 1.4 -10.8 89.2 
0.1 0.083±0.009 10.5 -16.5 83.5 
0.2 0.176±0.002 1.2 -11.9 88.1 
0.4 0.433±0.016 3.7 8.3 108.3 
0.8 0.742±0.040 5.3 -7.2 92.8 
QCL* 0.041±0.001 3.3 -18.6 81.4 
QCM 0.218±0.012 5.3 -13.7 87.3 
QCH 0.444±0.007 1.6 -11.2 88.8 
*n=12 
 
 
 
 
 
 
 
 
 45 
 
2.2.4 Carry-over 
Carry-over was evaluated by placing vials of blank mobile phase at different locations in the 
analysis set especially after the highest standard and QC. There was no carry-over evident in any 
of the blank reagent samples that were proven by the absence of any peaks in chromatogram 
corresponding to 4-pyridoxic acid. 
2.2.5 Recovery 
Recovery of 4-PA from urine was assessed by spiking analyte into water at the same 
concentrations as that of the quality control samples. Two spiked samples of each concentration 
(QCL and QCH) were analyzed using standard curves generated from urine based standards as 
described previously. Recovery after protein precipitation was compared with original 
concentration. Means, standard deviations and coefficients of variation were calculated. QCL 
recovery from urine was (76±0.15%) vs. (104±0.76 %) from water and QCH recovery from 
urine was (88±0.05%) vs. (89.1± 6.81%) from water. Results are shown in Table 10. Recovery 
calculation from urine standards and quality control samples were performed throughout the 
validation and was always ≥80%. 
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Table 10. Recovery from urine and water 
Recovery 
 Concentration (µM) 
URINE 
Concentration (µM) 
WATER 
QCL QCH QCL QCH 
Conc. Recovery 
% 
Conc. Recovery 
% 
Conc. Recovery 
% 
Conc. Recovery 
% 
1 0.038 75.8 0.44 88.1 0.052 104.7 0.42 84.3 
2 0.038 76 0.44 88.0 0.053 105.3 0.47 93.9 
Mean 0.038 75.9 0.44 88.0 0.053 105.3 0.45 89.1 
SD 0.00 0.15 0.00 0.05 0.00 0.76 0.03 6.8 
CV% 0.197 0.2 0.053 0.053 0.72 0.72 7.7 7.7 
 
2.2.6 Stability 
Bench-top short-term stability after 1h and 4h at room temperature was studied to verify 
if 4-pyridoxic acid degraded over the course of analyses. Short-term stability was evaluated by 
analyzing triplicate of both QCL and QCH that was kept at room temperature before the 
extraction step. The CV% and deviation % as well as recovery were within the acceptable limits 
of validation. Results are shown in Table 11. The auto sampler stability was evaluated by leaving 
triplicates of both QCL and QCH samples at room temperature for 24h followed by HPLC 
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analysis. Both QCL and QCH CV%, Deviation % as well as recovery % were within the 
acceptable standard limits of validation. The results are shown in Table 12.  
Long-term stability was studied in order to ensure that 4-pyridoxic acid in urine samples 
did not undergo degradation under the storage conditions before being analyzed. Triplicate 
samples of both QCL and QCH after 3 thaw-freeze cycles were analyzed to evaluate stability. 
The results of CV %, deviation %, and recovery % were within acceptable validation limits. 
Results are shown in Table 13.   In addition, long-term stability was studied using triplicates of 
matrix-based QC’s (QCL and QCH) stored at −80 ◦C for 3 months. The results for CV%, 
deviation % as well as recovery % were within the acceptable limits of validation. Results are 
shown in Table 14. 
 
Table 11. Bench-top stability 
  4-Pyridoxic Acid Standards (µM) 
 
QCL-
1HR QCL-4HR QCH-1HR QCH-4HR 
 0.05 0.04 0.49 0.49 
 0.04 0.04 0.49 0.49 
 0.04 0.04 0.49 0.49 
Mean 0.05 0.04 0.49 0.49 
SD 0.005 0.002 0.001 0.001 
CV % 9.9 5.8 0.2 0.3 
Deviation % -6.4 -18.6 -2.5 -2.6 
Recovery % 93.6 81.4 97.6 97.4 
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Table 12. Auto sampler stability 
 Concentration(µM) 
Replicate QCL QCH 
1 0.05 0.49 
2 0.05 0.49 
3 0.05 0.49 
Target 0.05 0.50 
Mean 0.05 0.49 
SD 0.001 0.000 
CV% 1.2 0.02 
Deviation % 3.6 -3.0 
Recovery % 103.6 97.0 
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Table 13. Long term stability 
  Long Term Stability 
Replicate QCL (0.05 µM) QCH (0.5 µM) 
1 0.05 0.44 
2 0.05 0.42 
3 0.05 0.44 
Mean 0.05 0.44 
SD 0.000 0.01 
CV% 1.05 2.34 
Deviation % 8.0 13.0 
Recovery % 92.0 87.0 
 
 
Table 14. Freeze/Thaw stability 
  Freeze /Thaw  
Replicate QCL (0.05 µM) QCH (0.5 µM) 
1 0.04 0.44 
2 0.04 0.46 
Mean 0.04 0.46 
SD 0.00 0.01 
CV% 1.04 2.09 
Deviation% -20.0 -8.0 
Recovery % 80.0 91.0 
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 The stability of the analyte (expressed as percentage recovery) at room temperature for 
1 and 4 hours, in the auto sampler for 24 hours, in the storage conditions after 3 months, and 
after 3-thaw-freeze cycles was evaluated by comparing the back-calculated concentration to that 
of the nominal concentration. The results showed that 4-pyridoxic acid is stable under tested 
conditions without any loss. All recovery values were within acceptable range.  
2.2.7 Dilution Analysis 
Individual samples were prepared for the linearity of dilution analysis at a concentration 
of 2x HQC.  Aliquots of the samples were then diluted 1:1, 1:2, and 1:4 with blank urine prior to 
analysis. Each dilution level was processed in triplicate and back calculated against the reference 
concentration. The mean accuracy and precision obtained for all dilution levels was within ≤20% 
and the recovery corresponding to nominal concentration was ≥ 80% according to FDA 
guidelines. The results are shown in Table 15. 
 
Table 15. Dilution Analysis 
  
4-Pyridoxic acid (1µM) 
 
Replicate 1:1 1:2 1:4 
1 0.41 0.26 0.13 
2 0.42 0.22 0.13 
3 0.43 0.20 0.14 
Mean 0.42 0.23 0.13 
SD 0.012 0.033 0.006 
CV % 2.8 14.4 4.2 
Deviation % -16.6 -8.7 6.6 
Recovery % 83.4 91.2 106.0 
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 2.2.8 Summary of validation results 
Table 16. Summary of validation results 
Validation Parameter 4-Pyridoxic Acid 
Linear Range (µM) 0.0125 – 0.8 
Correlation Coefficient (mean of 3) 0.9971 ±0.0041 
Inter-day Accuracy (% Deviation) QCL n=36 (0.05 μM) -16.3 
 QCM n=18 (0.25 μM) -4.92 
 QCH n=18 (0.5 µM) 1.47 
Inter-day Precision (%CV) QCL n=36 (0.05 μM) 5.19 
 QCM n=18 (0.25 μM) 7.17 
 QCH n=18 (0.5 µM) 3.35 
Intra-day Accuracy (% Deviation) QCL n=12 (0.05 μM) 
Day1 
Day2 
Day3  
 
17.9 
-9.4 
4.47 
 QCM n=6 (0.25 μM) 
Day1 
Day2 
Day3 
 
-20 
-2.7 
2.1 
 QCH n=6 (0.5 µM) 
Day1 
Day2 
 
-18.6 
-13.7 
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Day3 -11.2 
 
Intra-day Precision (%CV) 
0.05 μM 
 
QCL n=12 
Day1 
Day2 
Day3 
 
3.6 
10.0 
4.4 
0.25 μM QCM n =6 
Day1 
Day2 
Day3 
 
3.6 
2.1 
1.2 
0.5 µM QCH n=6 
Day1 
Day2 
Day3 
 
3.3 
5.3 
1.6 
Dilution Analysis  Precision CV% 
1μM 
1:1 
1:2 
1:4 
2.8 
14.4 
4.2 
Dilution Analysis  Accuracy 
Deviation % 
1μM 
1:1 
1:2 
1:4 
-16.6 
-8.7 
6.6 
Stability 
QCL(0.05 μM), QCH(0.5 μM) 
Bench-Top stability 1Hr, 
4Hr, Freeze/Thaw stability, 
Long Term Stability, auto-
sampler after 24 Hr 
Recovery ≥80% 
Recovery Acceptable recovery of 
≥80% or ≤120% 
From urine 
matrix 
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2.3 DISCUSSION 
An analytical methodology for quantification of 4-pyridoxic acid in urine is described. 
Full validation according to the FDA guidelines was performed, and the limit of quantification 
level of 0.0125 µM was reached for 4-pyridoxic acid, with accuracy and precision levels within 
FDA requirements.  
Previous analytical methods involved fluorescence detection in combination with pre-
column or post-column derivatization. These assays utility is limited by the additional chemical 
modification of the analyte despite the reported enhancement of the detection potential and 
sensitivity. The fluorescence detection used is sensitive to pH and temperature changes. Post- 
column derivatization used different modifying agents such as sodium bisulfite [71, 75] and 
chlorite [72]. Pre-column conversion served the same purpose by adding the modifying agent 
before the chromatographic separation. Modifying agents such as cyanide are not routinely used 
by laboratories, because of toxicity and safety concerns [70]. Another method utilized similar 
HPLC settings as described here but used a coulometric detection. This method of measuring of 
different compounds by electrochemical detection is subjected to non-specific interference by 
endogenous compounds [73].  Other more sensitive analytical techniques were reported in 
literature including the use of ultra-performance liquid chromatography-tandem mass 
spectrometry. However, these techniques are costly and reserved for the use when detection of 
levels is needed in minimal volumes of samples such as in cerebrospinal fluids [76]. 
 
  The method of separation utilized the polar feature of 4-pyridoxic acid as an analyte. The 
use of sodium polysulfonate as an ion-exchanger in the mobile phase accompanied by 
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adjustment of pH of the mobile phase is utilized to optimize the separation of 4-pyridoxic acid 
from other urinary components. The UV spectrophotometric detection was implemented at the 4-
pyridoxic acid peak absorption wavelength (λmax=302 nm). The lower limit of quantification 
was determined as the lowest detectable concentration that maintains the accuracy and deviation 
within the 20% margin. The Calibration curve, quality controls were prepared as described and 
the validation assay was carried out.  
The calibration curve in urine was linear with a satisfactory correlation of coefficient of 
>0.99.  However, the intercept was not close to zero even after treating the urine with activated 
charcoal. The intercept is likely due to endogenous 4-pyridoxic acid or other endogenous 
chemicals. To reduce this source of interference, multiple sources of urine were pooled into one 
urine source and then treated with activated charcoal. The further testing for accuracy, precision 
and recovery was all within the acceptable range for the lower concentration of 20% margin for 
both accuracy and precision and of 80% for recovery. The rest of standards were similarly, 
within the 15% margin of acceptance for precision and accuracy and within the 80% acceptable 
limit for recovery.  
The bench top stability, auto-sampler stability, short term stability, freeze/thaw as well as 
long term stability were all acceptable with ≥80% recovery. The analyte (4-pyridoxic acid) was 
detected in a reasonable short retention time of about 10 minutes with no evidence of carry-over. 
The quality control samples were utilized to evaluate the validity of the analytical method and all 
runs were accepted whenever the QC’s run was optimal.  
This HPLC-UV detection assay is achieved by the use of reversed-phase by addition of 
ion pairing (sodium heptanesulfonic acid). The gradient mobile phase was adjusted in terms of 
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optimal buffer, ion-paining agent, and methanol concentration. The peak was detected on a 
reasonably short time of 10 minutes that compared to other methods.  
Limitation of the assay development and validation were limited to issues like 
interference from the matrix. The urine was treated with activated charcoal to obtain a blank 
standard that is free of interference. To improve the quality of work and minimize variability, 
repetitive measures of multiple replicates was practiced throughout the assay development and 
validation. The sample preparation, quality control preparation, and mobile phase preparation 
might lead to some variability, however following standard laboratory procedures and protocols 
minimize such a source of variation.  
2.4 CONCLUSION 
An analytical methodology for quantification of 4-pyridoxic acid in urine is described. 
Full validation according to the FDA guidelines was performed, and the limit of quantification 
level of 0.0125 µM was reached for 4-pyridoxic acid, with accuracy and precision levels within 
FDA requirements. 
This method is suitable for the estimation of 4-pyridoxic acid in urine samples as a 
precursor of vitamin B6 status. It can be useful as a non-invasive technique to monitor vitamin 
B6 metabolites especially in patients who may experience deficiency due to high rate of 
degradation like in small bowel transplantation. The method was utilized to analyze the clinical 
urine samples from small bowel transplant patients. The analytical method is simple and the 
sample preparation is easy and the time of run is conveniently short. This analytical assay has an 
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adequate sensitivity to detect the 4-pyridoxic acid levels in urine without the need for chemical 
derivatization or post-column treatment like the existing fluorescent assays.  This assay is easy to 
use with acceptable accuracy and precision and can be utilized conveniently to analyze clinical 
samples from different patient population. 
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3.0  VITAMIN B6 STATUS FOLLOWING SMALL BOWEL TRANSPLANTATION 
Abstract: A deficiency in vitamin B6 was identified in small bowel transplant patients in a 
previous study and this study focused on investigating various mechanisms that are likely to 
contribute to such a deficiency. Urinary metabolite of vitamin B6 (4-pyridoxic acid) was 
measured using a validated HPLC method in small bowel transplant patients at two different 
time points after small bowel transplantation (early session within three months post 
transplantation and late session after more than three months post transplantation) and compared 
to matching healthy control subjects. Blood samples were also collected for the measurement of 
alkaline phosphatase, serum albumin and cytokines in these subjects. Transplant recipients had a 
significantly higher cumulative amount of 4-pyridoxic acid excreted in the urine when compared 
to control subjects. The amount of 4-PA was higher in the early post transplantation time period, 
compared to the later post transplantation time period. The concentrations of alkaline 
phosphatase in plasma were also significantly higher in transplant patients at both time periods 
than in control subjects. On the other hand, the serum albumin levels were lower in the transplant 
patients when compared to control group at both time periods as well. Certain cytokines (IL-1β, 
IL-2, and INF-γ) were notably elevated in the transplant patients when compared to control 
subjects. The study results suggested that increased degradation of vitamin B6 to 4-pyridoxic 
acid that was mediated by alkaline phosphatase as a probable primary cause of vitamin B6 
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deficiency in small bowel transplant patients. In addition, the lower concentration of serum 
albumin to which pyridoxal 5` phosphate binds may lead to higher free fraction of pyridoxal 5’ 
phosphate and that correspondingly will increase the degradation of vitamin B6.  This study is 
the first to investigate mechanistically the fate of the vitamin B6 metabolites in a transplant 
patient population. 
3.1 INTRODUCTION 
The success of solid organ transplantation is primarily due to advances in 
immunosuppressive therapy. The major concerns with organ transplantation in the 1980’s were 
high graft failure rates and frequent episodes of acute rejections. However, with new agents, like 
cyclosporine and tacrolimus, the rejection rates are much lower and the graft and patient survival 
has improved significantly. Eventually, the attention has shifted from preventing acute rejection 
to balancing that with less adverse effects. Nutritional status of transplant patients has gained 
attention recently, as many of the patients undergoing transplantation are nutritionally vulnerable 
[77].  For example, the transplant candidates especially for small bowel transplantation will be 
usually receiving parenteral nutrition (PN) for their nutritional support. 
Vitamin deficiency has been observed in various organ transplant patients. Vitamin B6 
deficiency has been reported in several organ transplant patients, as discussed earlier (chapter 2). 
Almost all small bowel transplant patients develop deficiency after nearly thirty days post 
transplantation. Nearly, 60% of liver transplant patients, 50 % of kidney transplant patients, and 
about 20 % of heart transplant patients have been reported to exhibit vitamin B6 deficiency.  
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Studies in humans have suggested that vitamin B6 deficiency affects the immune function, and 
the main clinical signs of vitamin B6 deficiency are the neurological manifestations [78].  
According to Matarese et al., increased metabolic demand induced by steroids, 
immunosuppressive agents used, and allograft status may alter vitamin B6 metabolism or 
absorption and ultimately might lead to vitamin B6 deficiency in small bowel transplant patients 
[9].  Small bowel transplant has been evolving into an effective therapeutic alternative for 
patients with intestinal failure. However, it is also associated with relatively heavier 
immunosuppression and many systemic complications. These include relatively high prevalence 
of post-transplant neurological disorders of 30-60%. The common causes for these exacerbations 
were attributed mainly to immunosuppressive medications, infections and the metabolic demand. 
A retrospective analysis (n=54) identified neurologic issues after receiving small bowel 
transplantation with about two years follow-up. These manifestations were distributed between 
headache (50%), encephalopathy (43%), seizures (17%), CNS infections (7%), neuromuscular 
complications (7%), and tacrolimus neurotoxicity (14%)  [79]. The nutritional status after small 
intestinal transplantation in a small cohort (n=46) showed an improvement and most of the 
patients restored their nutritional autonomy and quality of life measures after one year follow-up. 
However, there was no micronutrient follow-up or analysis in this study [80]. A prospective 
study with a five year follow-up involved 376 intestinal and multivisceral transplant recipients 
and reported an overall incidence of 18% of neuropsychiatric disorders that includes bipolar 
disorder, depression, anxiety, and peripheral neuropathy. These were significantly higher in 
pediatric recipients than in adults [81]. The improvement in nutritional status after intestinal 
transplantation in children (n=11) measured by weight Z-score and some biochemical parameters 
1 year post small bowel transplantation was rather global. The study did not address specific 
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micronutrient status and relevant manifestations [82]. The intestinal absorption rate in children 
after small bowel transplantation (n=24) was shown to be suboptimal. However, this study relied 
on the ratio of ingested and absorbed energy to resting energy expenditure but specific 
micronutrient status was not addressed [83]. 
The immunosuppressive management following intestinal transplantation has been 
changing with the ultimate goal of reducing the incidence of acute rejection, which is the most 
prominent risk factor. Traditionally, the regimens include tacrolimus, rapamycin and steroids as 
well as different induction strategies with almtuzumab, daclizumab, rituximab and 
thymoglobulin. These different strategies led to different rates of acute rejection, survival and 
infections [84, 85].  The nutritional and intestinal effects of various immunosuppressive agents 
were addressed with several different agents. A significant decrease in intestinal nutrient 
absorption with agents like tacrolimus, rapamycin, as well as mycophenolic acid has been 
reported in rats. The mechanisms of those effects were not clearly elucidated and a metabolic 
effect such as impaired ATP-production was suggested [86, 87]. The intestinal dysfunction due 
to short term use of immunosuppressive drugs (tacrolimus, cyclosporine, mycophenolate mofetil, 
sirolimus and azathioprine) using in vitro rat jejunum model were controversial and suggested 
the disturbed resorption of glucose that might lead to malabsorptive diarrhea [88] or no effect on 
glucose absorption, chloride secretion or barrier function [89, 90].  
The effect of tacrolimus on small bowel function is thus far not documented in small 
bowel transplant recipients.  Immunosuppression with tacrolimus or sirolimus reduced cellular 
and molecular inflammatory events and subsequent dysmotility in the intestinal transplant graft 
in rats [91]. Tacrolimus had no documented effect on vitamin B6 metabolism in rats. However, a 
benefit of tacrolimus was evident in heart transplant recipient with elevated levels of 
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homocysteine, which is related to vitamin B6 [92]. In contrast, the effect of tacrolimus on 
homocysteine in cultured proximal tubule epithelial cells in vitro was not observed [93]. In 
addition, tacrolimus inhibited the vitamin B6 dependent tryptophan degradation in human 
peripheral blood mononuclear cells in vitro [94]. Tacrolimus is considered the main 
immunosuppressant used in small bowel transplantation, however with several adverse events 
that include neurotoxicity. A case of tacrolimus associated ischemic optic neuropathy and 
posterior reversible encephalopathy syndrome after small bowel transplantation has been 
reported, but the mechanism of toxicity was not further investigated [95]. 
Cytokines are among the markers that are regularly measured in various solid organ 
transplantations. Cytokines are of special interest in small bowel transplantation as the activation 
of intestinal immune system cells is much higher than that of analogous peripheral cells. 
Interleukine-6 (IL-6) and tissue necrosis factor-α (TNF-α) are among the usually monitored 
markers. (96) Interleukin-6, among other inflammatory markers in swine model small bowel 
transplantation showed a transient elevation following the surgery that returned to baseline in 
few days [97]. However, the chronic allograft rejection showed an elevated IL-6, TNF-α, and IL-
10 after 60 -90 days following small intestine transplantation in rats [98]. Although, there is no 
association reported to date between inflammatory markers and vitamin B6 metabolism, vitamin 
B6 supplementation has been shown to improve pro-inflammatory responses in patients with 
rheumatoid arthritis. Plasma IL-6 and TNF-α levels were significantly decreased after 12 weeks 
of vitamin B6 supplementation when compared to control group [99]. 
An early hypogammagloulinemia was reported following small bowel transplantation 
(n=34) and about 59% of small bowel transplant patients developed this deficiency during the 
early post-transplant period with a mean of 10 days [100]. Serum Albumin following small 
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bowel transplantation also serves as a potential predictor for recovery. Serum albumin level 
during intestinal transplant rejection (n=26) was significantly lower than baseline levels [101]. 
Pyridoxal 5’ phosphate is mainly bound to albumin that preserves it from further degradation by 
alkaline phosphatase and aldehyde oxidase. Lower levels of albumin can lead to increased 
degradation of vitamin B6.  
Vitamin B6 deficiency has been reported in several organ transplant patients and almost 
in all small bowel transplant patients as mentioned in earlier chapters. Vitamin B6 deficiency 
was reported in as much as 96% in small bowel transplantation, 60 % of liver transplant patients, 
50% of kidney transplant patients, and 20% of heart transplant patients. Increased levels of 
alkaline phosphatase, which plays an important role in degradation of P5P, had been reported 
under different conditions in liver transplant patients as well as few cases with kidney 
transplantation. Despite the fact that tacrolimus is not known to increase alkaline phosphatase 
levels, these case reports indicate that the levels of alkaline phosphatase should be monitored 
during tacrolimus treatment.  
The proposed mechanisms for vitamin B6 deficiency in transplant populations include 
the increased metabolic demand that will exhaust the vitamin B6 sources, inadequate intake, 
abnormal metabolism (decreased formation), or drug interaction [9]. Chiang and coworkers 
reported that inflammation such as in rheumatoid arthritis may cause depletion in vitamin B6. 
The plasma P5P level in rheumatoid arthritis patients was 24.7 nmol/L compared to 46.2 nmol/L 
in a control group [102]. On the other hand, despite the dietary intake in some of these patient 
groups, the deficiency still occurred. Finally, a metabolic abnormality is most likely to occur, 
either due to decreased formation (inhibition of pyridoxal kinase) or increased degradation 
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(increased alkaline phosphatase and/or less protein binding). This last mechanism has never been 
evaluated in this patient population. 
Small bowel transplant patients are at the highest risk for developing vitamin B6 
deficiency. The hypothesis that this organ transplantation is associated with stronger immune 
response and so elevated inflammatory markers like alkaline phosphatase and cytokines is 
expected in small bowel transplant patients. We predicted a higher urinary 4-PA, higher serum 
alkaline phosphatase, higher cytokine levels and/or lower serum albumin in small bowel 
transplant patients than in healthy subjects that may contribute to the observed low vitamin B6 
levels. This study was designed to quantify the urinary excretion product 4-pyridoxic acid (4-PA) 
in small bowel transplant patients after transplantation at two time periods. The levels of 4-PA 
were measured using validated HPLC method.  Plasma Alkaline phosphatase and serum albumin 
were also measured in the central laboratory as part of routine clinical care. Selected plasma 
cytokines was also measured at different follow up visits as biomarkers of interest. 
3.2 CLINICAL STUDY 
All plasma and urine samples were obtained from small bowel transplant patients who 
had participated in a study that was approved by the University of Pittsburgh Institutional 
Review Board and had provided informed consents for the collected samples to be used in 
additional investigations.  
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3.2.1 Clinical Study Design 
 The primary study was performed in small bowel transplant patients and a healthy 
control group with no renal or hepatobiliary diseases. The inclusion criteria included: age 
between 18-65, with body weight within 30% of ideal body weight, patients who received small 
bowel transplantation, and signed the IRB approved informed consent. Transplant candidates 
were excluded if they had a history of previous organ transplant, a creatinine clearance less than 
30 ml/minute, hemoglobin less than 8.5 gm/dL, or were smokers. Any patient on known 
pyridoxal kinase inhibitor was also excluded. These include: R-roscovitine, 4-deoxypyridoxine, 
cycloserine, D-penicillamine, dopamine, isoniazid, levodopa, muzolimine, progabide, 
thiamphenicol and theophylline. All supplemental vitamin B6 intakes were recorded. 
Transplanted subjects were not studied after transplant if they required supplemental oxygen, 
were receiving a non-standard immunosuppression protocol or had a clinical or histological 
evidence of acute or chronic rejection. 
Control subjects were age and gender matched healthy subjects. The inclusion criteria 
were age between 18 and 65 years, weight within 30 percent of ideal body weight, and normal 
renal and hepatic function. Subjects were excluded if they were smoking, or have a history of 
intestinal diseases like Crohn’s disease.  
Study design: Transplant subjects underwent two separate study sessions, one in the early 
post- transplant period while patients were still in the hospital after surgery and one four to 
fourteen months after transplantation. Cumulative urine samples (~10 ml) from 0-12 hours were 
collected after transplantation and the total volume was recorded. Similar collections from a 
group of healthy volunteers were also performed. The urinary concentrations of 4-PA was 
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measured using HPLC. The amounts were then calculated given the volume of urine, as (volume 
x concentration). Alkaline phosphatase and albumin serum concentrations were recorded 
throughout the study as part of routine clinical care. Blood samples were collected across the 
study time for selected cytokine analysis 
Statistical analysis:  Sample size calculation for power of 80% and level of significance 
of 0.05 was calculated depending on the reported concentrations of P5P in intestinal transplant 
population before and after transplantation [9]. P5P concentrations were 14.6±13.5 ng/ml and 
2.42±0.08 ng/ml, before and after transplantation, respectively. Assuming two independent 
samples and 1:1 ratio patient to control, the sample size calculated (for power of 80% and level 
of significance of 0.05) is 22 (11 in each group). The effect size is estimated to be 1.28 and  can 
be utilized to measure the strength of relationship between the treatment and control group. (G 
Power 3.1.0, 2009) 
All data was plotted and tested for normality before further statistical analysis. The 12-
hour cumulative amounts of 4-pyridoxic acid were normally distributed over the time interval.  
The average cumulative total 4-PA excreted in urine over 12 hours was compared between 
control group and the transplant groups using analysis of variance (ANOVA) with α level of 
0.05. Urinary 4-PA was compared between groups with control for different confounding 
variables like gender and parenteral status (PN). Similar, comparisons using ANOVA were 
carried out for alkaline phosphatase, albumin and each of the measured cytokines. Subgroup 
analysis was pursued by dividing transplant group into an early transplant session (<30 days) or 
Late transplant group (>30 days). The sub-group analysis was basically a t-test for these 
subgroups and the control keeping the same level of significance as 0.05. In addition, post-hoc 
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Bonferroni correction test was used to compare the two-tailed p-values with the corrected 
reduced α value between different groups. The new level of significance used is α/n. 
3.2.2 Subjects 
Transplant recipients were recruited prior to transplant, either in the outpatient transplant clinic 
or as inpatients during hospital admissions not related to transplantation. Twelve small bowel 
transplant recipients underwent study session 1 between post-transplant day 10 and 40, six 
subjects of the session one had complete 12 hour urine collection with volumes recorded. Out of 
the six transplant subjects who underwent study session 1, two were men and four were women. 
Seven subjects returned for the second study session and only six had complete 12 hour urine 
collection (two males and four females). Sixteen healthy age-gender matched control subjects 
participated in the study, however four of them were excluded from analysis as they were on 
multivitamin supplement. All transplant recipients were Caucasians. None of the study subjects, 
controls or transplant, were taking known pyridoxal kinase inhibitors at the time of study. 
However, some of the transplant subjects were taking some type of supplementation or receiving 
parenteral nutrition (PN). All transplant patients had tacrolimus as their primary 
immunosuppressant. Of note, all transplant patients were taking proton pump inhibitor during the 
study sessions (lansoprazole, pantoprazole or omeprazole were given, typically once per day). 
All transplant subjects required corticosteroid treatment as methylprednisolone, hydrocortisone 
or prednisone administered through different routes at some point either during or after 
transplant. Transplant subjects received nystatin swish and swallow for candida esophagitis 
prevention, sulfamethoxazole / trimethoprim 400/80 mg tablet by mouth three times a week for 
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prevention of Pneumocystis carinii (PCP) pneumonia and either oral or intravenous ganciclovir 
for cytomegalovirus (CMV) prophylaxis.   
All transplant patients received other medications, including antihypertensives, 
antidepressants, and warfarin. Table 17 summarizes the demographics of the participants 
included in the analysis of this study in both transplant and control groups.  
 
 
Table 17. Demographics of the participating groups in the clinical study 
Number of Participants Control (n=12) 
Transplant (n=12, 6 each session) 
Age Control ( 21-56 Years) 
Transplant (23-60 Years) 
Gender Control ( M=5) 
Transplant (M=5) 
Multivitamin intake Control (n=0) 
Transplant (n=3) (PN) 
TPN Control ( n=0) 
Transplant (n=3) 
Post Operation Day  
(POD) 
Transplant  
10-40 days (n=6) 
125-428 days (n=6) 
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3.2.3 4-Pyridoxic acid measurement in urine 
Urinary 4-Pyridoxic acid was measured using the validated HPLC assay developed in our 
laboratory (previously described) with convenient sensitivity and specificity according to FDA 
guidelines for validation of bio analytical assays. Urine samples were collected up to 12 hours 
Calibration curve was constructed using the concentrations (0.0125 – 0.8 µM). The calibration 
curve was prepared from a pooled urine samples that was treated similarly to the samples from 
both control subjects and patients.  
3.2.4 Results and Discussion 
Higher amounts of urinary 4-PA indicated more degradation of P5P and increased excretion as 
a mechanism of vitamin B6 deficiency. Higher plasma alkaline phosphatase levels observed are 
expected to be responsible for increased degradation of P5P. Lower albumin levels indicated 
more of free P5P in plasma that could have facilitated increased degradation as well. Individual 
levels of selected cytokines during different stages of transplantation highlighted the 
inflammatory component that was evaluated further. 
4-PA cumulative amounts were plotted to see how the values are distributed. Most of the 
4-pyridoxic acid urinary excreted amounts were centered around the mean as shown in the 
following graph. However, the small number of healthy volunteers is a limitation for the test of 
normality. Normal 4-PA urinary excretion is >1.5 µmol/12hr the distribution is shown in Figure 
5 
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 Figure 5. Distribution of urinary 4-pyridoxic acid in healthy volunteers (n=12) 
 
The Cumulative 12-hr Urinary 4-PA in control was (1.11 µmol± 0.13) compared to that 
in transplant group (16.92 µmol±3.58). Large variation in the transplant group was observed 
compared to the control group. Single Factor ANOVA is used to compare groups, and the p-
value is <0.05 between small bowel transplant group and the control group (Figure 6).  This is 
the first report to our knowledge that documents increased urinary excretion in the small bowel 
transplant patients.  
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Figure 6. Cumulative 12-hr urinary 4-pyridoxic acid in control (n=12) and transplant 
(n=12) groups 
 
For further analysis the transplant group was divided into two distinct groups according 
to their post-operative days (POD). Transplant session 1 was for all patients for whom their POD 
is less than 30 days and Transplant session 2 was for all patients whom their OD is more than 30 
days. The variation in results was the highest during the transplant session 1. Amounts of 4-PA 
excreted were (1.11 µmol ±0.13), (23.78 µmol ±5.96), and 10.1 µmol ±1.4) in control, group at 
transplant session 1 and at transplant session 2, respectively. The Statistical analysis using single 
factor ANOVA between groups showed statistically significances. Then the post-hoc Bonferroni 
correction test was used to compare the two-tailed p-values with the corrected reduced α value 
between different groups. The new level of significance is α/n =0.0167. The comparison between 
control group and either group of transplant sessions showed a significance difference (C vs. 
TX1 p-value< 0.0167), (C vs. TX2 p-value<0.0167). In addition, there was not a statistically 
 71 
 
significant difference between the transplant session 1 and the transplant session 2 (p-value > 
corrected α= 0.0167) (Figure 7).  The analysis suggests that there is significantly higher urinary 
excretion of 4-pyridoxic acid following transplantation in small bowel transplant patients. This 
effect was obvious at early session following transplantation; however, the higher urinary 
excretion of 4-pyridoxic acid was also maintained at the late post-transplant session. This might 
be explained by continuously increased degradation of P5P following transplantation that may be 
sustained long term after transplantation. 
 
 
Figure 7. Cumulative 12-hr urinary 4-pyridoxic acid in control (n=12) and transplant 
groups (n=6) 
 
The transplant group and the control group consisted of 7 females and 5 males. As 
expected there was no statistical difference between males and females in the control group. In 
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control groups, the mean value in females was (1.11 µmol±0.21) vs. (1.1 µmol±0.0.11) in males. 
ANOVA single factor found a significant difference between all groups control males, control 
females, transplant females, and transplant males (p-value <0.05). The post-hoc analysis using 
Bonferroni correction revealed no statistically significant difference between gender subgroups. 
The results in transplant group also was not statistically significant, however there were overall 
higher levels of 4-PA in females as well as higher variation (F 20.33 µmol±5.93, M 12.15 
µmol±0.9). The two-tail p-value was > 0.0167. The National Health and Nutrition Examination 
Survey 2003-2004 (NHANES) (n=9000) indicated that plasma P5P concentrations of women of 
childbearing age (n=2048) were significantly lower than those of comparably aged men 
(n=2351), especially in women using oral contraceptives. These were more prevalent in 
subgroups of smokers, elderly, non-hispanic blacks, and current and former oral contraceptive 
users. The gender differences in vitamin B6 status were attributed to estrogen intake that might 
interfere with P5P dependent tryptophan metabolism [8].  
Parenteral Nutrition (PN) status is not uncommon among the small bowel transplant 
patients and can be a confounding factor in interpretation of this result. A comparison among the 
transplant subjects controlling for their PN status confirmed that higher 4-PA urinary amounts 
were observed among subjects receiving PN. The 4-PA levels were statistically significant 
higher in patients receiving PN accompanied by a higher variation (PN 36.9 µmol± 2.4, No-PN 
10.7 µmol±0.93), p-value <0.05). However, the number of patients who were on PN after 
transplantation was low (n=3) in comparison to patients who were not on PN. The confounding 
effect of PN can be tested with larger sample size analysis on both groups.  
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Figure 8. Cumulative urinary 4-PA amount in transplant groups according to PN status 
 
The control group (1.11 µmol± 0.13) and the transplant group not receiving PN (10.28 
µmol± 0.93) were compared by Single factor ANOVA and the comparison showed a statistical 
difference regardless of PN status. The conclusion is that the 4-pyridoxic acid urinary levels are 
not as a result of supplementation with PN; rather it is an ongoing process that promotes 
degradation independent of intake.  
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Figure 9. Cumulative urinary 4-PA amount in control and transplant groups controlling 
for PN status 
 
This graph suggested that increased 4-pyridoxic acid excretion is predominant following small 
bowel transplantation regardless of intake. Many patients of small bowel transplant patients will be given 
TPN for variable time periods in order to regain the functional status of the transplanted organ.  
Limitations: The study had limited number of subjects who participated. The urine collection for 
extended period of time with the volume recording was a challenge to get a complete set of urine 
samples for 12-24 hours. The variability in patient clinical condition, medication regimen as well 
as individual variation is also another confounder factor. All analysis was carried out by 
assuming the normal distribution, which is hard to document, given that the sample size is 
relatively small. However, the developed validated HPLC assay served as a powerful analytical 
tool to track the metabolic product of vitamin B6.  
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3.2.5 Alkaline Phosphatase 
The normal levels of alkaline phosphatase in normal healthy adults range between 30 – 140 
IU/L. This inflammatory marker is measured regularly to monitor for signs of acute rejection and 
is of special interest in our case as it accelerates the degradation of Pyridoxal 5 Phosphate (P5P) 
into its ultimate urinary metabolite 4-PA.  Average alkaline phosphatase (ALKP) was (56.8 IU/L 
±3.7) for control group and (112.5 IU/L ±18.4) for transplant group.  Even though average levels 
in both groups are within normal range, they were statistically significantly different (p-value < 
0.05) (Figure 10). 
 
 
 
Figure 10. Plasma alkaline phosphatase levels in control (n=12) and transplant group 
(n=12) 
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 Group comparison between different transplant groups as per session and control group using 
single factor ANOVA showed no statistically significant difference (p-value=0.052). Also, the 
comparison between transplant sessions and control group showed a statistical significance 
between transplant session 2 and control group (p-value< 0.05). The session 1 transplant group 
patients alkaline phosphatase is statistically significant from control at α=0.05 (p-value < 0.05). 
However, with post hoc analysis with Benferroni correction there is not a significant difference 
between both groups. Finally, there is no statistically significant difference between transplant 
sessions in terms of alkaline phosphatase levels (Figure 11). 
Control vs Transplant                                                           NS 
Control vs Transplant session 1                                           P<0.05 
Control vs Transplant session 2                                           P<0.05 
Transplant session 1 vs Transplant session 2                       NS 
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Figure 11. Alkaline phosphatase levels in control (n=12) and different transplant groups 
(n=6 each) 
 
 
Abnormal vitamin B6 metabolism has been reported in alkaline phosphatase knock-out 
mice. These animals eliminated the active coenzyme P5P into urine which strengthen the 
hypothesis that alkaline phosphatase plays an important role in the metabolism of P5P [103]. The 
increased levels of alkaline phosphatase seem to shift the metabolism towards more degradation 
of P5P into the inactive metabolite (4-pyridoxic acid). These finding of elevated alkaline 
phosphatase after transplantation that is sustained until late session might explain the increased 
degradation of P5P into 4-pyridoxic acid. Hydrolysis of pyridoxal 5` phosphate (P5P) in plasma 
was demonstrated in patients with conditions of elevated alkaline phosphatase and some hepatic 
abnormalities. This study inferred an inverse relationship between the plasma levels of Pyridoxal 
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5` phosphate and the alkaline phosphatase levels (r=0.893, p-value <0.001). This study provides 
evidence that vitamin B6 deficiency might be explained by increased degradation of pyridoxal 5` 
phosphate by elevated levels of alkaline phosphatase [104].  
Limitations: As alkaline phosphatase is an inflammatory marker that can be elevated in many 
conditions and can be variable in activity depending on the source. In our study, we measured 
plasma alkaline phosphatase regardless of its source. The relationship between elevated alkaline 
phosphatase and increased degradation of pyridoxal 5’ phosphate has been suggested, however 
the study design being observational in nature cannot conclude the causality. An alkaline 
phosphatase knock out animal can serve as a model to evaluate the exact role of alkaline 
phosphatase in the increasing degradation of P5P. 
3.2.6  Serum Albumin 
The normal range of albumin in healthy adults is 3.4 – 5.4 g/dl. Pyridoxal 5’Phosphate 
(P5P) is predominantly bound to albumin in plasma and only the unbound P5P will be subject to 
alkaline phosphatase mediated further degradation into ultimate 4-PA urinary metabolite.  
Average albumin level was compared between control group and transplant group.  Albumin 
levels were measured frequently following transplantation and serum samples were collected for 
albumin measurement. The laboratory results for these transplant subjects were extracted from 
the patient chart. The control subject serum albumin were ordered and recorded as the 
comparison group. Average serum Albumin was (4.0 g/dl ±0.14) in the control group and (3.4 
g/dl ±0.08) in the transplant group. Though levels in both groups were within normal range, they 
were statistically significantly different from one another (p-value < 0.05) (Figure 12). 
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Figure 12. Serum albumin levels in control (n=12) and transplant group (n=12) 
 
Single factor ANOVA showed a statistically significant difference between groups 
(control subjects, transplant session 1 and transplant session 2), p-value <0.05.  Furthermore, 
subgroup comparison using the post-hoc Bonferroni correction between different transplant 
groups and control group revealed a statistically significant difference between transplant session 
1 and transplant session 2 and the control group with p-values <0.0167 (Figure 13). Albumin 
status is very important for the distribution of the active vitamin B6 form (pyridoxal 5` 
phosphate). Low levels of albumin may increase the free fraction of pyridoxal 5` phosphate 
which makes it more prone to degradation by alkaline phosphatase and aldehyde oxidase.  
 80 
 
  
Figure 13. Serum albumin levels in control (n=12) and different transplant groups (n=6) 
 
Lower serum albumin levels, the main binding protein for the active P5P in plasma, may 
result in the active form being more prone to degradation by alkaline phosphatase, which is also 
elevated. This can account for the increased degradation of P5P into 4-pyridoxic acid. The levels 
of albumin in small bowel transplant were lower than in that of control subjects despite the fact 
that they are all within normal range. The extent of this possible effect is difficult to quantify but 
it could be another contributing factor to the observation of increased degradation product in the 
urine. A study that investigated the increased hydrolysis of pyridoxal 5` phosphate due to 
increased alkaline phosphatase in different non-transplant hepatobiliary disorders measured 
serum albumin as the main binding protein to P5P.  Interestingly the hydrolysis rate in one hour 
did not bear any relationship to the albumin levels, which ranged from 26g/L to 47g/L [104]. 
Limitations: albumin is an endogenous compound that is affected by many variables 
including liver function, trauma, and medications. The levels of albumin can vary extensively 
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throughout the course of study in these patients due to their clinical status as well as their dietary 
intake. However, the overall effect was expected and that suggested a probable role for low 
albumin levels in increasing the degradation of P5P. 
3.2.7 Cytokine Analysis 
Cytokines are functional proteins that are mainly produced by immune cells like 
macrophage and lymphocytes as well as other cells like epithelial cells and smooth muscle cells. 
In organ transplantation, cytokines are indicators for acute phase response and organ rejection. 
Many cytokines are known to have an effect on activity and expression of some metabolizing 
enzymes and/or transporters. For example: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL12, TNF-α, 
IFN-γ [105, 106, and 107]. Table 18 summarizes the effect of different cytokines on metabolic 
enzymes and or transporters. 
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Table 18. Cytokines effect on metabolism and normal ranges 
Cytokine Effect on Metabolism/ 
Transporter 
Normal range 
IL-1β CYP3A4,MRP(2,3,4),BCRP, 
OATP1, MDR1 
0.96 ± 0.12 pg/ml 
IL-2 MDR1 0.3 ± 1.4 pg/ml 
IL-4 NA 1.4 ± 5.4 pg/mL (range 0-27) 
IL-6 CYP3A4, CYP1A2, CYP2C19 1.2 ± 2.4 pg/mL 
IL-8 NA 9.76 ± 1.31 pg/mL 
IL-10 NA 6.4 ± 15.0 pg/mL 
IL-12 NA of less than 10 pg/mL 
TNF-α CYP3A4,MDR1, CYP2C19 1.3 ± 2.6 pg/mL 
IFN-γ CYP3A  of less than 5 pg/mL 
 
 
Blood was withdrawn from control subjects once and at several time points post small 
bowel transplantation and aliquots were assayed for selected human cytokines: interleukin-1β 
(IL-1 β), interleukin-2 (IL-2), interleukin-4 (IL4), interleukin-6 (IL-6), interleukin-10 (IL-10), 
interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and interferon-γ (INF-γ).  
All assays were carried out at Luminex core facility. These cytokines were measured in 
plasma using a MILLIPLEX MAP High sensitivity Human Cytokines Multiplex Panel kit (# 
HSCTTO-60SK, Millipore, Billerica, MA). Reagents included in the kit were a high sensitivity 
human cytokine standard, high sensitivity human cytokines quality controls 1 and 2, serum 
matrix containing 0.08% sodium azide, 96-well filter plate with sealers, 10X wash buffer 
containing 0.05% Proclin, high sensitivity human cytokine detection antibodies, and 
streptavidin-phycoerythrin solution.  The bead based multiplexing assay is simply where the 
beads have fluorescent dyes that will produce a specific spectral address upon conjugation with 
the analyte of interest. This technology, although very expensive, allowed multiple detections of 
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several cytokines with a very small sample volume. Each individual cytokine average was 
compared between transplant and control group. There were a total of 80 blood samples for 
analysis including control samples and the rest were a mix of session 1 and session 2 transplant 
subjects. Two plates were run to accommodate all samples. 
Frozen plasma samples were thawed, mixed, and centrifuged to remove particulates. 
Following the manufacturer directions the standard curves were constructed using quality 
controls and serum matrix to different concentrations (0.13, 0.64, 3.2, 16, 80, 400, and 2,000 
pg/ml). Twenty five µL of premixed antibody beads were then added to each well then an 
additional 50 µL of each of the standards and the quality controls were added to the designated 
wells along with 50 µL of serum matrix. To this whole mix a 50 µL of buffer and the sample are 
subsequently added. The filled plate is then sealed and incubated overnight on a shaker at 4⁰C. 
The different standard curve range for different cytokine is shown in Table 19. 
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Table 19. Standard curve range for different cytokines 
Cytokine Standard Curve range (pg/ml) 
Plate 1 Plate 2 
IL-1β 0.13 -359.24 0.79-334.65 
IL-2 0.13 -2122.24 0.77 -2395.94 
IL-4 3.72 -2002.91 3.02 – 2000.03 
IL-6 0.14 -2156.73 0.79 – 343.75 
IL-8 0.13 -1721.55 0.13 – 2308.77 
IL-10 3.25 -2019.26 3.08 -2018.59 
IL-12 0.72 -2034.93 0.83 -2050.18 
TNF-α 0.13 -2286.95 0.14-366.14 
IFN-γ 0.16 – 2010.6 4.15 – 2027.17 
 
 
The next day, the mixture was removed and the plates were washed with buffer solution. 
Fifty µL of detection antibodies were added to each well and the plate resealed and incubated at 
room temperature for an hour on a plate shaker. An additional 50 µL of streptavidin-
phycoerythrin was added to each well and similarly incubated for another 30 minutes. Finally, 
the wells were washed out and all fluids were removed. The beads in the wells were re-
suspended by 100µL of sheath fluid. 
Finally, the plates were read on a Luminex 100 analyzer (Luminex Corporation, Austin, 
TX). The Fluorescent intensity (FI) output was analyzed using Bio-Plex Manager software (Bio-
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Rad Laboratories, Hercules, and CA). A minimum of five points were used to generate each 
standard curve. Points were excluded from the curve if the (observed concentration/expected 
concentration)*100 was less than 70 or greater than 130. 
Statistical significant difference between either transplant session and control group are 
summarized in Table 20. The results were expressed as average observed values ± standard error 
as the number of samples that was reported in each session for different cytokines were variable. 
IL-6, IL-8, IL-10, TNF- α were significantly higher during the early transplant session when 
compared to controls. Using ANOVA analysis, both IL-6, and TNF-α were significantly higher 
in transplant patients in both session 1 and 2 than in control group. Both IL-8 and IL-10 were 
significantly higher than in control during transplant session 1. The rest of the cytokines were not 
significantly different from control group.   
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Table 20. Plasma cytokine analysis shown as average ± standard error in transplant different 
sessions and control subjects 
 
Cytokine 
Transplant 
Session 1 
Obs. Conc. ±SE 
(pg/ml) 
Transplant 
Session 2 
Obs. Conc. ±SE 
(pg/ml) 
 
Control 
Obs. Conc. ±SE 
(pg/ml) 
P-value 
Single Factor ANOVA 
IL-1β 0.90 ±0.17 0.78 ± 0.13 1.18 ± 0.26 0.43 
IL-2 0.74 ±0.11 0.81 ± 0.11 0.70 ±0.19 0.17 
IL-4 7.2±1.40 8.24±0.83 6.18±1.79 0.63 
IL-6 14.0±2.32 4.93 ±1.52 1.27±0.17 0.003  
IL-8 20.6±2.4  4.81±1.39 1.68±0.13 <0.0001 
IL-10 57.9 ±5.3 10.74±2.40 5.84±0.76 <0.0001 
IL-12P70 2.3 ±0.60 3.32 ±1.52 1.46±0.36 0.29 
INF-γ 7.6 ± 2.8 5.85±2.67 3.54 ± 0.65 0.54 
TNF-α 7.2±0.83 3.11±0.30 1.43±0.15 <0.0001 
  
 
The following series of graphs is a representation of different cytokines in both transplant 
sessions and control group. IL-6 and TNF-α were significantly higher than control groups in 
small bowel transplant patients in both transplant sessions. IL-6 average plasma concentration is 
significantly higher than that in control subjects. Single factor ANOVA analysis was significant 
in between groups analysis (p<0.05). The post-hoc Bonferroni correction confirmed the 
statistically significance difference between session 1 and the control group (p<0.0167). The 
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comparison between session 2 and the control group is only statistically significantly different at 
p-value <0.05. The comparison is shown in Figure 14. And, the “*” denotes the statistically 
significant difference.  
 
 
Figure 14. IL-6 mean plasma concentration in control (n=12) and different transplant 
groups (n=6 each) 
 
TNF-α average plasma concentration is significantly higher than that in control subjects. 
Single factor ANOVA analysis was significant in between groups analysis (p<0.05). The post-
hoc Bonferroni correction confirmed the statistically significance difference between both 
session 1 and session 2 when compared to control subjects (p-value <0.0167). The comparison is 
shown in Figure 15 and, the “*” denotes the statistically significant difference. 
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Figure 15. TNF-α mean plasma concentration in control (n=12) and different transplant 
groups (n=6 each) 
 
The following cytokines showed a statistical significance difference between transplant 
session 1 group and control group, these are IL-8 and IL-10. IL-8 average plasma concentration 
is significantly higher than that in control subjects. Single factor ANOVA analysis was 
significant in between groups analysis (p<0.05). The post-hoc Bonferroni correction confirmed 
the statistically significance difference between only session 1 and the control subjects (p-value 
<0.0176).  The comparison is shown in Figure 16 and, the “*” denotes the statistically significant 
difference. 
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Figure 16. IL-8 mean plasma concentration in control (n=12) and different transplant 
groups (n=6 each) 
 
IL-10 average plasma concentration is significantly higher than that in control subjects. 
Single factor ANOVA analysis was significant in between groups analysis (p<0.05). The post-
hoc Bonferroni correction confirmed the statistically significance difference between session 1 
and control subjects (p-value <0.0167).  The comparison is shown in Figure 17 and, the “*” 
denotes the statistically significant difference. 
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Figure 17. IL-10 mean plasma concentration in control (n=12) and different transplant 
groups (n=6 each) 
 
The rest of cytokines showed no statistical difference between either transplant groups or 
the control group, and this group includes: (IL-1β, IL-2, IL-4, IL-12p70, and INF-γ). Single 
factor ANOVA analysis was not significant in between groups analysis (p>0.05). The post-hoc 
Bonferroni correction confirmed there is no statistically significance difference between both 
session 1 and session 2 when compared to control subjects.  NS in the graphs stands for not 
significant difference.  
Limitations: the assay for cytokine analysis is labor intensive and expensive that limited 
the types of cytokines measured. However, the nine cytokine panel measurement was convenient 
and feasible as it includes almost all commonly reported cytokines in different transplant 
patients. The technique used based on Multiplexing that allows the measurement of all cytokines 
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in one sample at the same time. Further studies might focus on the notably elevated cytokines 
which might be better option to utilize resources.  
3.3 CONCLUSIONS 
In recent study by Matarese et al., the P5P deficiency occurred in 96 % of small bowel 
recipients within a median of onset of 30 days (range 4-118 d) after transplantation. About 41% 
of these patients received parenteral nutrition. The main finding was undetectable P5P 
concentration. This finding explained the clinical observations of unexplained neuropathy or 
myopathy in a few of long-term survivors. However, underlying cause for such a deficiency was 
not clearly identified. The authors suggested an increased metabolic demand along with drugs 
used for immunosuppression as a cause of the observations [9].    
This clinical study reveals a possible mechanism for the biochemical deficiency of 
vitamin B6 post transplantation in small bowel transplant population. The increased urinary 
metabolite 4-pyridoxic acid suggested strongly that more degradation of the active form 
pyridoxal 5’ phosphate is occurring. This was supported by the elevated levels of non-specific 
alkaline phosphatase throughout the study period. As the active form need to lose its phosphate 
group in order to get converted to its ultimate urinary 4-pyridoxic acid by aldehyde oxidase. The 
elevated urinary 4-pyridoxic acid in transplant group in early session and even few months after 
transplantation was the main finding in this clinical study. Merrill et al. suggested that vitamin 
B6 deficiency in patients with cirrhosis was attributed to increased dephosphorylation e.i 
degradation  rather than altered formation of pyridoxal 5` phosphate. In addition, the serum 
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albumin levels in patients with cirrhosis were also lower than the control subjects, which is also 
similar to our finding regarding lower serum albumin in the small bowel transplant patients 
[108]. 
The higher levels of 4-pyridoxic acid in transplant groups is supported by the finding of 
increased alkaline phosphatase levels in the transplant groups in addition to lower levels in serum 
albumin. This last factor might lead to increasing degradation level of pyridoxal after getting 
dephosphorylated by alkaline phosphatase. As less albumin may lead to more of free unbound 
pyridoxal 5` phosphate that is consequently more available to get dephosphorylated and 
ultimately degraded by aldehyde oxidase into urinary 4-pyridoxic acid.  
 In addition, P5P is predominantly bound to albumin in circulation, which gives another 
layer of protection against degradation. The significantly less than control average albumin 
among transplant patient – although within normal range- also suggested relatively more free 
P5P will be subjected to alkaline phosphatase and further degradation into 4-Pyridoxic acid.  
The cytokine analysis showed the majority of cytokines are not different from the control 
healthy groups. The few cytokines that showed elevation following transplantation had no 
reported influence on pyridoxal kinase activity. However, IL-6 and TNF-α were significantly 
higher in transplant groups than in controls and only IL-8 and IL-10 were significantly higher 
than control in the early session follow-up. The role of cytokines on vitamin B6 status is not 
clear and will be evaluated. There is a body of evidence that suggested a cytokine effect on 
different metabolic enzymes like CYP enzymes and some transporters; however, there is no 
supporting evidence in such an effect on pyridoxal kinase enzyme activity or expression. 
However, a variety of inflammatory disease conditions have been found to be associated with 
low levels of plasma pyridoxal 5` phosphate without any indication of a lower dietary intake of 
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vitamin B6. The Suggested explanation is the mobilization of this co-enzyme (P5P) to sites of 
inflammation for use in P5P dependent enzymes [109]. Also, vitamin B6 status, based on 
pyridoxal 5` phosphate levels in plasma was identified in different inflammatory diseases such as 
cardiovascular diseases, rheumatoid arthritis, inflammatory bowel disease, and diabetes. A study 
in a population of U.S. adults (n=2229) suggested a strong inverse relationship between P5P 
levels and some inflammatory markers including cytokines such as IL-6 and TNF-α [110].  
In summary, our prediction of increased urinary excretion of 4-PA was confirmed. The 
proposed mechanism was attributed to increased alkaline phosphatase in plasma following small 
bowel transplantation. As the degradation of P5P was likely promoted by increased alkaline 
phosphatase levels, this reflected by higher urinary 4-PA excretion in small bowel transplant 
subjects. In addition, the lower albumin levels in small bowel transplant subjects may lead to 
increased free fraction of P5P, that likely lead to more degradation of P5P free fraction by 
alkaline phosphatase. Finally, the blood analysis revealed elevation of some pro-inflammatory 
cytokines that might have a role on P5P metabolism.  
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4.0  COMPUTATIONAL APPROACH TO PREDICT DRUG INTERACTIONS WITH 
PYRIDOXAL KINASE 
Abstract: 
Small bowel transplant patients on an average receive 12 different medications. There is 
always a high probability for drug-drug interactions or drug-enzyme interactions. A 
computational approach to test the effect of complex regimen of medications on the activity of 
an enzyme involved in vitamin B6 metabolism was designed and carried out. The crystal 
structure of pyridoxal kinase enzyme was imported into the computer and the spatial binding 
sites were identified. All different drugs were also saved into a format compatible (SDF) for the 
operating system. The docking score was the primary outcome of this fitting exercise where the 
higher the docking score is the more likely the drug will spatially fit and the interaction is more 
likely to occur. For the validation purposes, known inhibitors were also tested under the same 
programming conditions. The scores were recorded and the probable high score compounds were 
further tested in vitro to confirm the results. Pantoprazole, a proton pump inhibitor that was used 
almost in all small bowel transplant patients, was among the list of drugs with high docking 
score (7.17) in addition only one immunosuppressive drug (mycophenolic acid) also showed a 
relatively high docking score (5.2). These two drugs were selected to be further tested in in vitro 
experiments that will be described in the later chapters. 
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4.1 INTRODUCTION 
Small bowel transplant patients usually receive a large number of medications for the rest 
of their lives. With this complex regimen, medications may play a role in the vitamin status 
given that there is a group of medication known for their inhibitory effect on pyridoxal kinase, 
the enzyme responsible for conversion of vitamin B6 into pyridoxal 5’ phosphate (P5P), the 
active form of vitamin B6. These known inhibitors are not typically used in this patient 
population and include the following: R-roscovitine, 4-deoxypyridoxine, cycloserine, D-
penicillamine, dopamine, isoniazid, levodopa, muzolimine, progabide, thiamphenicol and 
theophylline. On the other hand, the small bowel transplant patients may take 10-15 different 
medications that have never been tested for their inhibitory effect on pyridoxal kinase. These 
medications include immunosuppressant, antibiotics, antivirals, antifungals, steroids and others. 
The median number of daily oral medications was 7 (4 – 11) in study session 1 and the median 
was 14 (10 -22) in study session 2. These medications were described in Table. 21. We utilized a 
computational approach to predict potential impact of drugs used in transplant patients described 
in chapter 3 on the activity of certain enzymes involved in the pathway of vitamin B6 
metabolism. 
 
 
 96 
 
  
Table 21. Medication used by transplant subjects during study sessions 
Medication Medication Medication 
Amlodipine Diphenoxylate / atropine Cholecalciferol 
Metoprolol Ganciclovir Calcium citrate + Vitamin. D 
Warfarin Acyclovir Folic acid 
Sertraline Valganciclovir Ferrous gluconate 
Trazodone Clonazepam Zinc sulfate 
Mirtazapine Zolpidem Riboflavin 
Bupropion Sodium bicarbonate Methylphenidate 
Hydromorphone Magnesium gluconate Levitracetam 
Loperamide Pyridoxine Pravastatin 
 
 
“Human Pyridoxal Kinase is a homodimer related by a non-crystallographic twofold axis 
in an asymmetric unit. Each pyridoxal kinase monomer contains nine α-helices (named α1-9), 
and 12 β-strands (named β1-10 and β-5a, β5b). Human pyridoxal kinase is an elongated dimer 
with the approximate dimensions of 85 Å x 60 Å x 40 Å. The dimer interface is formed between 
α1, α9, β1, and β3 from each monomer with a non-crystallographic twofold symmetry through 
hydrogen bonding, salt bridges, and hydrophobic interactions. The buried area is approximately 
about 13% of the total surface area in one monomer. The dimer interface has hydrophobic 
residues Ile-15, Ile-35, met-74, and Met-287 that facilitate a strong hydrophobic interaction 
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between monomers of pyridoxal kinase. The binding site is a cavity with negative charge located 
along one edge of the central β-sheet that attracts substrates with positive charge, such as the 
pyridine ring of vitamin B6 and the adenine ring of ATP. The ATP-binding site is located in a 
shallow groove formed by the hydrophobic side chains of surrounding residues. On the opposite 
direction of ATP binding site the pyridoxal-binding site is located.” [111]. 
4.2 METHODS 
An innovative computational approach to predict drug interactions with pyridoxal kinase 
was utilized .The crystal structure of Pyridoxal kinase were simulated into the computer and all 
medications that would be used by typical small bowel transplant patient were docked and the 
score were calculated. All known inhibitors (virtually) were used as control for this 
computational exercise. SYBYL® from Tripos was utilized for receptor ligand modeling. 
Pyridoxal is the typical substrate for this enzyme that has a pyridoxal binding pocket and an ATP 
binding pocket where phosphorylation takes place.   
4.3 RESULTS  
Pyridoxal kinase crystal structure was identified through a known chemical structures 
library and the PDB ID was 1 RFU where the red color represents α-helices and the blue color 
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represents the β-strands. Figure 18 is a computer generated snap shot of our enzyme and Figure 
19 is another representation that showed the ATP-binding pocket. 
 
 
Figure 18. Pyridoxal kinase crystal structure, PDB ID: 1RFU  
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Figure 19. Pyridoxal kinase with ATP-binding pocket 
 
The Known inhibitors were used to validate our spatial configuration and return relatively 
high docking scores that are shown in Table 22. The lead substrate pyridoxal was used as the 
reference value (docking score= 3.01) and is shown in Figure 20.  
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Table 22.  Docking scores of known pyridoxal kinase inhibitors  
Inhibitor Docking Score 
Deoxypyridoxine 6.41 
Levodopa 5.31 
Roscovitine 4.55 
Dopamine 4.36 
Thiamphenicol 4.16 
Cycloserine 4.12 
Theophylline 4.05 
Muzolimine 4.02 
Isoniazid 3.95 
Progabide 3.24 
 
 
 
Figure 20. Pyridoxal (Lead substrate), Docking score=3.01 
 
All medication used or may be used throughout the course of their post transplantation 
were docked and the docking scores were calculated. Compounds like tacrolimus were not likely 
to score high because of the huge size but other compounds were a finding that granted us a 
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justification for further testing. The chemical structures of all these compounds were gathered 
and saved as SDF files that were compatible with the software. The docking scores for all these 
tested medications are shown on Table 23. Notably, pantoprazole scored the highest (7.17) 
(Figure 21). Interestingly, the only immunosuppressive drug mycophenolic acid score was 5.2 
and all the other immunosuppressive drugs (tacrolimus, sirolimus, and cyclosporine) scored very 
low (Figure 22). The results with these large molecules were anticipated.  
 
Table 23. Docking score of different drugs used in transplant patients at pyridoxal kinase as 
target enzyme 
Drug Docking Score Drug Docking Score 
Pantoprazole 7.17 Voriconazole 3.58 
Trimethoprim 6.54 Fluconazole 3.09 
Acyclovir 5.48 Pyridoxal 3.01 
Valganciclovir 5.44 Prednisone 2.65 
Mycophenolic acid 5.2 Methyl prednisone 2.38 
Ganciclovir 4.91 Tacrolimus -15.52 
Ranitidine 4.87 Nystatin -81.92 
MMF 4.79 Sirolimus -133.32 
Sulfamethoxazole 4.33 Cyclosporine -389.80 
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Figure 21. Pantoprazole, docking score=7.17 
 
 
 
Figure 22. Tacrolimus, Docking score=-15.52 
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4.4 CONCLUSION 
The computational approach gave us an insight into which drugs are likely to interfere 
with the pyridoxal kinase activity. This virtual approach was utilized in early drug discovery and 
in identification of probable targets. The concept was utilized since we have the crystal structure 
of the enzyme was available and the medications used for prediction of any possible drug 
interaction. All compounds were screened for fitness to target enzyme and the docking scores 
suggested few of the drugs as a good fit. The higher the docking score the better is the inhibitory 
effect and the compounds with lower docking score is not likely to be an inhibitor.  
Tacrolimus is not likely to fit into pyridoxal kinase pocket due to its large molecular 
structure. In addition, direct complexation reaction with pyridoxal 5 phosphate is not likely, as 
the chemical structure of tacrolimus shows no free primary amine group; therefore the formation 
of Schiff base complex like isoniazid and other known pyridoxal kinase inhibitors is not feasible. 
Schiff base is formed by condensation of aldehyde or ketone with primary amines. Further 
testing for these compounds were included in the upcoming studies to further explain whether 
this spatial configuration fitness can or will translate to effect on activity or expression of 
pyridoxal kinase. Several drugs notably have a high docking score like pantoprazole (7.17) and 
trimethoprim (6.54). Compounds with high score were tested using human hepatocytes and the 
pyridoxal kinase expression was determined.  
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5.0  PYRIDOXAL KINASE EXPRESSION AND ACTIVITY  
ABSTRACT: 
Pyridoxal kinase is the enzyme that is responsible for activation of vitamin B6 vitamers 
into pyridoxal 5’ phosphate (P5P), which is the ultimate active form of vitamin B6. Human 
hepatocyte cultures were used to study the effect of some drugs as well as some cytokines on the 
enzyme expression by measuring the mRNA expression using RT-PCR. Tacrolimus, 
pantoprazole, mycophenolic acid, IL-1, IL-2, and TNF-α were all evaluated for their effect on 
mRNA expression of pyridoxal kinase in cultured human hepatocytes. Both Tacrolimus(20 μg/L) 
and TNF-α inhibited the mRNA expression of pyridoxal kinase (p-value <0.0049). These results 
support the prediction that immunosuppressive drugs regimen based on tacrolimus and/or certain 
cytokines may affect the expression of pyridoxal kinase enzyme in liver.  
The activity of pyridoxal kinase was evaluated in human liver extract and cultured human 
hepatocytes. The activity was assessed by adding the probe substrate pyridoxal and by 
consequently measuring the pyridoxal 5’ phosphate metabolite. The acute effect of different 
tacrolimus concentrations on pyridoxal kinase activity in liver extract were compared with the 
known inhibitor 4-deoxypyridoxin. The chronic effect of different concentrations of tacrolimus 
and various cytokines on the activity of pyridoxal kinase in human hepatocytes cultures was 
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evaluated as well. The liver extract treatment with tacrolimus showed no effect on activity 
regardless of concentration. The hepatocyte treatment showed some inhibitory effect at ≥10μg/L 
tacrolimus concentrations and with some cytokines (IL-1β, IL-2, TNF-α). These results support 
the hypothesis of that tacrolimus (minimally) as well as some of the cytokines (significantly) 
may contribute to the reduced activity of pyridoxal kinase. 
 
 
5.1 PYRIDOXAL KINASE EXPRESSION AND IN HUMAN HEPATOCYTES 
 
5.1.1 Introduction 
Pyridoxal kinase enzyme that is mainly responsible for the formation of pyridoxal 
5’phosphate (P5P) was studied after treating human hepatocytes with different cytokines, various 
concentrations of the primary immunosuppressant (tacrolimus), pantoprazole and mycophenolic 
Acid (MPA), using the known inhibitor 4-deoxypyridine as control. The expression was 
evaluated by RT-PCR following the detailed protocol described later. 
Human Hepatocytes are widely used in metabolism studies due to their reduced 
complexity and its relevance to the human liver function. However, the low expression levels of 
drug metabolizing enzymes and lack of continuous availability are among the disadvantage of 
this system. In addition, the lack of co-factor providing cells, such as Kupffer cells may render 
 106 
 
these systems inefficient [112]  The living system of hepatocytes, although relatively short lived, 
is convenient for the inhibition studies that will take 3-5 days in length.  
5.1.2 Methods 
Human Hepatocytes were received from Dr. Steven Strom Laboratory at the University 
of Pittsburgh. They were prepared from livers not suitable for transplantation. Hepatocytes were 
isolated by a three-step collagenase perfusion technique and plated on collagen coated 6 well 
plates. Cells were cultured in hepatocyte maintenance media (HMM) and maintained at 37 ⁰C 
incubator throughout the experiment.  Media were changed every 24 hours. 
Hepatocytes were pre-treated with different concentrations of tacrolimus for 3 days that 
were within the therapeutic range (0, 2, 5, 10, 15, 20 μg/L). Additional plates were used for the 
following cytokines (IL-1, IL-2, TNF-α) at 10 ng/ml concentration that represent cytokine 
concentrations used in similar studies. These cytokines were selected as these three were 
reported in the literature for their effect on the metabolizing enzymes and transporters [106]. 
Two plates were used for pantoprazole and mycophenolic acid (MPA) at concentration of 4 
µg/ml, which is close to the maximum concentration observed in plasma in patients on these 
medications. These two medications had the highest docking scores. On day 4, media were 
removed from the plates and cells were washed twice in ice cold phosphate buffered saline 
(PBS). Total RNA was extracted using 1 ml of Trizol according to manufacturer’s protocol. The 
scraped samples were kept at -80 ⁰C until further RT-PCR analysis. Purified total RNA was 
reverse transcribed at using appropriate primers for pyridoxal kinase in addition to house-
keeping gene (Cyclophillin), accordingly. 
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The following process was followed for primer design, using “Nucleotide” library in” 
PubMed”, the search was conducted by encoded gene’s name “PDXK” with specifying the 
species as humans (Homo Sapiens. The selected mRNA was chosen and a sequence was picked. 
The entire gene sequence was copied and utilizing “BLAST” program to identify sequence 
similarities. The region that has the longest distance between two adjacent exons was chosen. 
The new sequence was pasted into http://frodo.wi.wi.mit.edu/ to get the following primers: 
 
Homo sapiens (PDXK) 1 
LEFT PRIMER         ctccatacagagccacgtca 
RIGHT PRIMER      acagagttcaccgcgtcaat 
Homo sapiens (PDXK) 2 
LEFT PRIMER         catacagagccacgtcatcc 
RIGHT PRIMER      cctgtgtggtttgaaaactgg 
A mixture of 50 µL of right and left primers were used in PCR reaction 
 
The samples were prepared according to standard protocol, trizol was added to tissues 
and homogenized in test tube, 200 µL chloroform was added into 1 ml of homogenate in an 
Eppendorf tube, total RNA extraction was continued according to protocol. (Appendix D). The 
following step aimed to reverse transcription, 11 µL of RNA extracted from previous step was 
added to 1µL of primer and dNTPs. After running samples in PCR for 5 minutes, buffer, DTT 
and reverse transcriptase enzyme were added to samples and ran in PCR (Two steps reaction). 
This process yielded the cDNAs. Two µL of cDNA resulted from previous step was mixed with 
SYBR green dye with buffer and primers specific to PDXK gene. Finally RT-PCR was run 
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according to the protocol in the manual. The following instruments were used: Eppendorf master 
cycler gradient 5331 (PCR), Eppendorf 5424 microcentrifuge with knobs and Applied Bio 
systems 7900HT Fast Real Time PCR System. 
5.1.3 Results 
The mRNA expression of enzyme was compared to house-keeping gene of choice. In our 
experiment PDXK was compared to Cyclophilin as the house keeping gene and the fold change 
was calculated. The method used for calculation is called (Delta Delta Ct Method) from 
manufacturer protocol. The following equations were used where X is the tested gene, HK is the 
house keeping gene, and C is the cycle number 
∆∆Ct = ∆Ct (Xtreat - HKtreat) - ∆ct (Xcontrol – HKcontrol), the fold change = 2(-∆∆Ct) 
All treatments when compared together with single factor ANOVA for the effect on 
pyridoxal kinase mRNA expression in hepatocytes. There was no significant difference between 
groups (P-value =0.132) as shown in Figure 23.  
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 Figure 23. Pyridoxal kinase mRNA expression in hepatocytes with different treatments,  
C: control, T: tacrolimus (2, 5, 10, 20 μg/L), IL-1: interleukin 1, IL-2: interleukin 2, TNF-
α: tissue necrosis factor α, Panto: Pantoprazole, MPA: mycophenolic acid 
 
The post-hoc Bonferroni correction analysis uncovers that TNF-α and tacrolimus at 
concentration 20 µg/L are statistically significantly different from the control in mRNA 
expression of pyridoxal kinase.  The expression study suggested that the rest of the drugs and 
cytokines do not have a direct inhibitory effect on the pyridoxal kinase enzyme. The statistical 
analysis is shown on Table 24. 
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Table 24. ANOVA post hoc analysis pyridoxal kinase mRNA expression in hepatocytes treated 
with drugs and cytokines 
Treatment P-value  
Bonferroni Correction 
 (<0.0049) 
Tacrolimus 2 µg/L 0.013718 
Tacrolimus 5 µg/L 0.015058 
Tacrolimus 10 µg/L 0.118384 
Tacrolimus 15 µg/L 0.070274 
Tacrolimus 20 µg/L 0.00357 
IL-1 0.305184 
IL-2 0.02129 
TNF-α 0.00019 
Pantoprazole 0.008077 
MPA 0.005301 
 
5.1.4 Conclusion 
Most of the treatments were not statistically different than the control in terms of 
inhibiting the mRNA expression of pyridoxal kinase in human hepatocytes. Only the post hoc 
comparison suggested that Tacrolimus at 20µg/L and TNF-α might have an effect on pyridoxal 
kinase expression. 
 111 
 
The computational docking exercise revealed that few medications may interact with 
pyridoxal kinase. Of the various drugs tested, pantoprazole scored the highest which led to 
further investigation. The RT-PCR experiment showed that only the highest concentration of 
tacrolimus tested had an effect on mRNA expression of pyridoxal kinase while other medications 
including lower tacrolimus concentrations, pantoprazole or mycophenolic acid had no effect on 
mRNA expression of pyridoxal kinase. Neither of these two agents was used in all patients who 
developed vitamin B6 deficiency. In addition, the cytokine (TNF-α) reduced the mRNA 
expression of pyridoxal kinase in hepatocytes, which suggested that this cytokine may also 
contribute to the observation in patients. Elevated levels of TNF-α were reported in small bowel 
transplant patients who developed vitamin B6 deficiency, which is consistent with current 
results. 
Elevated serum levels of IL-2, IL-6, and TNF-α had been reported in the early session 
(about 40 days) following small bowel. (113) Also IL-6 mRNA expression in the transplanted 
small bowel tissues was up regulated significantly early in the reperfusion phase during 
transplantation [114]. These results suggested an important role for certain cytokines in small 
bowel transplantation, but the effect on pyridoxal kinase activity or expression had not been 
reported before.  
Limitation: the expression study was solely focused on the mRNA pyridoxal kinase 
which is highly specific and sensitive utilizing the quantitative RT-PCR. However, the pyridoxal 
kinase protein expression was not measured or evaluated and that can be hard to interpret. A 
western blot targeting pyridoxal kinase will confirm that the expression is affected accurately. 
RT-PCR used has an advantage of being feasible, reproducible and highly sensitive.  
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 5.2 PYRIDOXAL KINASE ACTIVITY IN HUMAN LIVER HOMOGENATE AND 
HUMAN HEPATOCYTE CULTURES  
5.2.1 Introduction 
Pyridoxal kinase is a cytosolic enzyme that is abundant in liver tissue. It is not clear how 
the vitamin B6 deficiency develops following organ transplantation. The approach used here is to 
evaluate the impact of all variables like immunosuppressive medications and elevated cytokines 
relevant to small bowel transplantation on the activity of pyridoxal kinase. The acute effect of the 
primary immunosuppressive drug (tacrolimus) was evaluated in human liver homogenate over 
range of concentrations. The chronic effect was evaluated using human hepatocytes cultures over 
a range of concentration of tacrolimus and with cytokines over a period of four days.  
5.2.2 Methods  
 The effect of acute treatment with tacrolimus on pyridoxal kinase activity in human liver 
homogenate was evaluated using pyridoxal as probe substrate. Pyridoxal kinase activity - 
expressed as pyridoxal 5’ phosphate conc. (µg/L)/mg protein.1hr-  was measured at different 
tacrolimus concentration that included the therapeutic concentrations (0, 2, 5, 10, 15, 20 μg/ml) 
in the presence of 20 μM Pyridoxal in (100 μg protein) liver cell homogenate, The inhibitor 4-
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deoxypyridoxine (10 μM) served as a control. All these treatment were done in triplicates and 
the Mean ± SE were compared to control. Pyridoxal 5’ phosphate was measured by HPLC. 
The effect of chronic treatment with tacrolimus on pyridoxal kinase activity in human 
hepatocytes was evaluated using pyridoxal as probe substrate. Hepatocytes were pre-treated 
with different concentrations of tacrolimus that included the therapeutic concentrations (0, 2, 5, 
10, 15, 20 μg/L), for three days, on day 4 the hepatocytes were treated with the tacrolimus in 
the presence of 20 μM Pyridoxal, the probe substrate for pyridoxal kinase. The inhibitor 4-
deoxypyridoxine (10 μM) served as a positive control. Pyridoxal kinase activity was expressed 
as pyridoxal 5’ phosphate conc. (µg/L)/106cells. All treatments were performed in 6-well plates 
and were compared to control. 
The effect of cytokines on pyridoxal kinase activity in human hepatocytes was evaluated 
in similarly like above. Human liver hepatocytes were treated with 50 pg/ml cytokines (IL-1α, 
IL-1β, IL-2, IL-4, IL-6, IL-10, TNF-α) for 3 days; 4-deoxypyridine was used as control 
inhibitor. On day 4 all hepatocytes were treated with the substrate (Pyridoxal) and incubated as 
previously described. Pyridoxal kinase activity was measured by measuring P5P formed with 
different treatments. All treatments were done in 6-well plates and the mean± SE were 
compared to control.  
5.2.3 Results 
Calibration Curve of Pyridoxal 5` Phosphate in Buffer was constructed using HPLC. 
The curve showed linearity over the concentration range tested with an R2 =0.999 as shown on 
Figure 24.  
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Figure 24. Pyridoxal 5’phosphate calibration curve in buffer 
 
 The formation of pyridoxal 5` phosphate in human liver homogenates was not affected at 
any concentration of tacrolimus. The pyridoxal kinase is a cytosolic enzyme that can be degraded 
by the proteases and peptidases upon liver homogenate preparation; however the buffer system 
included inhibitors for these enzymes. The tissue levels of tacrolimus at the human liver are 
undefined so we tested multiple concentrations of tacrolimus. In addition, a high concentration of 
the substrate was justified in order to make the substrate available to the enzyme and to have 
detectable amounts of the metabolite within one hour. The pyridoxal kinase activity measured by 
P5P concentration/mg protein in 1 hour treatment was compared to the control and to the 
positive inhibitor 4-doxypyridoxine treatment. The results after one hour treatment showed no 
difference from the control as shown in Figure 25. 
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Figure 25. Pyridoxal 5’ phosphate level in human liver homogenate after treating with 
different concentrations of tacrolimus (n=3) 
The comparison between different P5P levels generated in presence of different 
concentrations of tacrolimus suggested that only tacrolimus can potentially inhibit pyridoxal 
kinase activity at higher concentrations. However the maximal inhibition did not exceed 20% 
even with the highest concentration (Figure 26). 
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 Figure 26. Pyridoxal 5’ phosphate level in human hepatocytes after treating with 
different concentrations of tacrolimus (n=6) 
 
The effect of cytokines on pyridoxal kinase activity was noted with IL-1β, IL-2, and TNF-α. The 
other cytokines did not have an effect on pyridoxal kinase activity in human hepatocytes system. 
However, all these cytokines were applied in a 50 pg/ml median concentration. The results are 
shown on Figure 27. 
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 Figure 27. Pyridoxal 5’ phosphate level in hepatocytes after treating with different 
cytokines (n=6) 
 
Limitations: the activity studies in hepatocytes resemble closely the living system; however is 
not exactly the same. The time of incubation with the substrate can be a variable, however an 
hour of incubation with the substrate can be extended in order to get more of the formation 
reaction might take place. The one hour incubation was adopted from other published 
experiments. 
The activity studies in the liver homogenate were utilized for the acute effect of different 
agents on pyridoxal kinase. The pyridoxal kinase is a cytosolic enzyme that can be degraded by 
the proteases upon homogenization or damaged by oxidation. However, the homogenizing buffer 
included phenylmethylsulfonyl fluoride as a serine protease inhibitor and butylated 
hydroxytoluene as antioxidant that terminate auto-oxidation. In addition, using a standard sample 
preparation protocol might help standardization of the procedure to minimize variation. 
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 5.2.4 Conclusion 
The primary hepatocyte cultures provided a living system that resembles closely the 
cellular system that include all cellular components being intact and the drugs would exert their 
action in a similar way like in vivo. However, the inhibition of pyridoxal kinase activity by 
tacrolimus in hepatocyte was marginal but yet statistically significant. The results showed that 
tacrolimus did not significantly affect the activity of pyridoxal kinase in human liver extract 
regardless of the concentration. The effect was comparable to the control while it showed a 
significantly different activity with the true positive control (4-deoxypyridoxine), which is a 
known inhibitor to pyridoxal kinase. However, tacrolimus effect on primary cultured hepatocytes 
was statistically significant at higher concentrations of tacrolimus (> 10 μg/L). 
Treating hepatocytes with IL-1β, IL-2, and TNF-α resulted in lower pyridoxal kinase 
activity, while other cytokines did not. These specific cytokines were reported in small bowel 
transplantation but their effect on pyridoxal kinase enzyme was not yet investigated. All these 
cytokines IL-1β, IL-2, TNF-α were reported in different literature for being elevated following 
small bowel transplantation and would sustain their higher than control levels for few months to 
a year following transplantation [113, 114]. The effect of different cytokines  on pyridoxal kinase 
activity  is a new finding that need to be further investigated. 
High concentrations of tacrolimus and selected cytokines appear to decrease the activity 
of pyridoxal kinase. This study provided support for the prediction that tacrolimus and cytokine 
(TNF-α) may contribute to altered pyridoxal kinase activity in patients.  
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5.3 EFFECT OF TACROLIMUS ON PYRIDOXAL 5’PHOSPHATE BINDING TO 
PLASMA PROTEIN 
5.3.1 Introduction 
Tacrolimus is the primary immunosuppressive agent used in small bowel transplantation. 
It has a very well characterized distribution in the body and binds to protein and red blood cells. 
On the other hand, pyridoxal 5’ phosphate (P5P) also has similar distribution profile which 
suggests another possibility for drug interaction. An in vitro protein binding study was carried 
out with different tacrolimus concentrations and the free P5P fraction was measured and 
compared to control. The results of the in vitro experiment did not suggest an important 
interaction.  
Tacrolimus is distributed in blood and plasma in a very similar fashion like the pyridoxal 
5` phosphate. Both bind to red blood cells and plasma proteins. The drug interaction in terms of 
binding was explored by mixing pyridoxal 5’ phosphate in plasma at different concentrations of 
tacrolimus and separating the bound P5P from the unbound P5P using ultrafiltration device, then 
measure the free pyridoxal 5` phosphate by HPLC. 
5.3.2 Methods 
Human plasma was incubated with various concentrations of tacrolimus (0, 2, 5, 10, 15, 20 
μg/L) and 20 µg/L pyridoxal 5’ phosphate (P5P), then ultra-centrifuged using the  Millipore 
ultrafiltration device. The supernatant was collected and the free P5P concentrations were 
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measured by HPLC. The calibration curve was constructed using HLPC conditions similar to 
what we used with buffer samples with an additional orthophosphoric acid pre-treatment step 
for sample preparation to precipitate the plasma proteins. The rest of the procedure was exactly 
the same as described earlier. 
 
5.3.3 Results 
The P5P calibration curve in plasma was linear across the concentration range used with 
R2=0.999 that indicated an excellent linearity. The calibration curve is shown in Figure 28. The 
results of the binding study showed minimal to no effect of tacrolimus on binding pyridoxal 5` 
phosphate to plasma protein. This might be explained by the higher affinity of the smaller 
molecule to bind to albumin than that of the larger tacrolimus. The results expressed as P5P 
percent bound in plasma are shown in Figure 29. 
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                              Figure 28. Pyridoxal 5’ phosphate calibration curve in plasma 
 
 
 
Figure 29. Percent pyridoxal 5’ phosphate bound in plasma treated with different 
tacrolimus concentrations (n=6) 
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Limitations: The plasma levels of free P5P along with albumin might provide a more 
accurate answer. The experiment suggested unlikely interaction at albumin level. 
 
5.4 CONCLUSIONS 
         
To support the hypothesis of the effect of drugs and/or cytokines on pyridoxal kinase 
activity and expression several in vitro evaluation tests were initiated utilizing human liver 
extract and human cultured hepatocytes. The activity of pyridoxal kinase was measured by the 
metabolic product of the probe substrate pyridoxal. The product pyridoxal 5` phosphate is the 
major metabolite that was measured in buffer and plasma using the adopted HPLC technique. 
The computational approach screened all the medications commonly used in transplant 
patients. Tacrolimus scored low and a direct interference with pyridoxal enzyme is not likely. 
Other medications like pantoprazole and mycophenolic acid had a high docking score and was 
evaluated in vitro for their potential interaction role. 
Pyridoxal kinase activity in human liver extract and human cultured hepatocytes was 
evaluated in the presence of different concentration of tacrolimus and several selected cytokines. 
Tacrolimus did not affect the metabolism of pyridoxal in human liver extract and showed some 
inhibition only at high concentration ≥10µg/L only in human hepatocytes.  The following 
cytokines (IL-1β, IL-2, and TNF-α) had an inhibitory effect on pyridoxal kinase activity in 
hepatocytes. 
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The in vitro testing utilized human liver extract for acute effect of different medications 
(tacrolimus, pantoprazole, and mycophenolic acid) on the activity of pyridoxal kinase. The result 
suggested no effect of tested drugs on pyridoxal kinase activity. The use of human hepatocytes 
cultures for chronic effect of these drugs and cytokines were evaluated for activity and 
expression. Only tacrolimus at higher concentrations 10-20µg/L and IL-1β, IL-2 and TNF-α 
showed an effect on inhibiting pyridoxal kinase activity in hepatocytes. The mRNA expression 
of pyridoxal kinase in hepatocytes were only significant with TNF-α and the highest tacrolimus 
concentration used (20µg/L).The plasma protein binding study with tacrolimus showed a no 
effect with all used tacrolimus concentrations. These findings support a probable role of 
cytokines in altering pyridoxal kinase activity and also that might be augmented by higher 
concentrations of tacrolimus. 
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6.0  PYRIDOXAL KINASE ACTIVITY AND EXPRESSION IN 
TRANSPLANTATION- OBSERVATION IN AN ANIMAL MODEL 
Abstract: 
Vitamin B6 deficiency appears to be present in all transplant patient population. A 
transplant model that does not involve an organ that participates in absorption, distribution, 
metabolism or excretion of medication provides an opportunity to test the impact of the effect of 
transplantation process and associated inflammation on vitamin B6 status. The composite 
allogenic transplant animal model where the hind limb was transplanted provided an excellent 
model to study the effect of transplantation of a remote organ that is highly immunogenic on the 
functional capacity of other tissues and organs in the body. Iso graft transplantation where the 
rejection should be absent, allogenic transplantation where the rejection is expected to happen 
with all its consequences and an allogenic transplantation where the immunosuppressive regimen 
is used, where rejection is prevented, was used in this study. It was possible to study the effect of 
transplantation, the acute rejection, and the effect of the immunosuppressive medication using 
this approach. The harvested livers extract were evaluated for pyridoxal kinase activity using 
pyridoxal as probe substrate. The total protein amounts in their liver extract were significantly 
less in all transplant animal groups and were the least in allogenic transplant group. The 
pyridoxal kinase activity and expression were less in the allogenic transplant group when 
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compared with all other groups. This study supports that transplantation surgery as well as the 
rejection process both contribute to decreased expression of pyridoxal kinase in the liver. The 
conclusion is that every time there is acute rejection the levels of inflammatory markers like 
cytokines and alkaline phosphatase will be increased and that might lead to increased vitamin B6 
degradation and deficiency or at least a higher need for vitamin B6 in transplant patients. 
6.1 INTRODUCTION 
Composite tissue allotransplantation (CTA) has drawn a lot of attention recently as an 
experimental model that target partial and complete faces, hands, forearms, arms, abdominal 
walls, bones, and bone-joint complexes. The whole process of transplantation, 
immunomodulation, rejection consequences, and therapeutic options are quite similar to other 
solid organ transplantation. Composite allotransplantation is known for its high immunogenic 
rejection response which might have effects on other non-transplanted organs in the body [115]. 
Unlike other allografts, the transplanted tissues in CTA are histologically heterogeneous, 
includes many tissue types (skin, muscle, bone, lymph nodes, nerves and tendons), and thus 
present variable immunogenicity of transplanted tissues to the host. This mandates intense and 
life-long immunosuppressive strategies [116]. Our utilization of this model is because of the 
augmented immunological response that might give us an insight for better understanding of the 
effect of transplantation and acute rejection on different non-transplanted organs like liver [117]. 
The mechanisms and mediators of inflammation in potential models for skin rejection in CTA 
had been partially understood. Chemokines or the cytokines with chemotactic activity for 
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leukocytes are reported to play an important role in the acute rejection processes and further their 
corresponding receptors expression up-regulation in various solid organ transplants as well as 
CTA models [118].    
We hypothesized that transplantation as process with its inflammatory cascade as well as 
the immune response may affect the functional capacity of the liver where most of the 
metabolism in the body took place. Pyridoxal kinase (PK) is mainly a hepatic enzyme that is 
responsible for the metabolism of vitamin B6 to its active precursor pyridoxal 5` phosphate. The 
animal model included an isograft rat group where same genetically matched animals were donor 
and recipient of the hind limb. The model also provided allogenic rat groups, where the donor is 
mismatched with the recipient and so that the rejection occurs.  Half of this group received 
antirejection regimen with tacrolimus and was not expected to be rejected. All these groups will 
be also compared to healthy non-transplanted control group of rats. The liver was the target 
organ of interest, where the activity as well as the expression of pyridoxal kinase was evaluated.  
6.2 METHODS 
6.2.1 Animals 
The study in rats was approved by Institutional Animal Care and Use Committee at 
University of Pittsburgh, Approval # 858. The use of rats in this experiment was justified by 
these animals being the smallest that may allow the surgeon to carry out the hind limb 
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transplantation. All rats were weighed 200–250 g and all animals were kept in individual mesh 
cages in a 12 hour day/night cycle.  
All surgeries were performed under sterile conditions using sterile instruments.  
Anesthesia was provided using sodium pentobarbital (50mg/kg, i.p). Surgical time was between 
3 to 5 hours. For the extended anesthesia Nembutal (10mg/kg) i.p booster doses was used. The 
depth of the anesthesia was assessed by movement of the animal and the frequency of 
respiration and by administering the toe pinch withdraw reflex test to the animal.  The donor 
animal’s hind-limb and groin were shaved, and the animal was placed in a supine decubitus 
position. The skin was prepped with betadine or chlorhexidine surgical prep, followed by 70% 
alcohol. An inguinal skin incision was made, exposing the epigastric vessels, which were 
cauterized.  The femoral sheath was identified and dissected out, separating the nerve, artery and 
vein components.  These were divided sharply ensuring adequate length for later anastomosis.  
Attention was then turned to the postero-lateral aspect of the limb, extending the skin incision, 
transecting the superficial muscle layer, and identifying and isolating the sciatic nerve.  The 
nerve was then sharply transected.  The remaining muscle groups were then transected to 
completely expose the mid-portion of the femur.  Using a sharp bone cutter, a 90 degree 
osteotomy was performed, and the allograft was freed from the remainder of the donor animal. 
The procedure was repeated to harvest the contralateral limb to minimize the number of donor 
animals required. Allograft donor animals were sacrificed following procurement of the 
allograft.  The recipient animal were shaved and prepped in a similar fashion under sterile 
conditions.  Implantation of the allograft proceeded with osteosynthesis using a 22-gauge needle 
as an intermedullary rod.  Major ventral muscle groups were reapproximated with 4-0 suture.  
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The femoral vein and then femoral artery were anastomosed using standard micro vascular 
technique and 10-0 suture. 
      Once the allograft was reperfused, the dorsal sciatic nerve was approximated in a similar 
fashion with 10-0 suture and the dorsal muscle groups were sutured together with 4-0 suture.  
Skin closure was performed using 4-0 silk in a running fashion. Skin sutures were absorbable 
and therefore do not require removal, minimizing the potential trauma to the recipient. All 
wounds were closed in an interrupted fashion in case the suture breaks. Once surgery was 
completed, the animals were then placed under a heat lamp until they were awake. Upon 
awakening the animals were transferred to the post-operative facility where they received food 
and water ad libitum.  
 
6.2.2 Study design 
The Lewis rats were assigned into four groups according to limb transplant allocation  
- Isograft group,(Auto)  
- Allograft group, (Allo) 
- Allograft treated with tacrolimus group, (Allo-Tac) 
- Control group (C) 
The tacrolimus treated group received intraperitoneal injection of 0.5 mg/kg/day. 
Animals were monitored for normal behavior and physiological function to ascertain their 
recovery from anesthesia, and assessment of pain/distress. The animals were warmed by 
circulating water heating pads or heat lamp and were monitored until the normal reflex was 
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regained.  Pain was alleviated with buprenorphine (0.1 mg/kg Q12 hours) for 3 days. The 
animals were allowed to ambulate in the post-operative period.  Limbs were evaluated daily for 
evidence of rejection or dehiscence of the suture. This involved observing the limb for 
occurrence of edema, erythema, epidermolysis, desquamation and mummification. The animals 
were monitored twice daily until sacrifice. When acute rejection occurred, respective animals 
were euthanized using an overdose of sodium pentobarbital (i.p, 100 mg/kg). We considered 
weight loss >20% of age matched controls to be significant.  All animals were observed daily for 
infection and weight loss of more than 20%.  
We expected that the group receiving no immunosuppression after transplantation will 
show evidence of rejection by 4-7 days based on past experience.  On day 5 post transplantation, 
animals were sacrificed and livers were collected and stored at – 80 °C until analysis for 
pyridoxal kinase expression.  
 
6.2.3 Liver homogenate preparation 
The livers were collected from each rat in each group on day 5 post operation. The livers 
were frozen in liquid nitrogen and kept at -80 ⁰C for expression analysis. The liver homogenates 
were prepared as described in Appendix A. Pyridoxal kinase enzyme is a cytosolic enzyme and 
so the supernatant was used after the centrifugation at 10,000 g for 20 minutes.  
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6.2.4 Total protein assay 
Total protein assay was performed utilizing the Lowry’s method. The calibration curve 
was constructed using bovine serum albumin (BSA) ranging in concentration from 0.025 – 0.4 
mg/ml. The UV absorption was measured using colorimetry at 750 nm. 
6.2.5 RT-PCR 
The pyridoxal kinase protein expression in different transplanted rat groups was 
measured by RT-PCR using actin as housekeeping gene. Purified total RNA was reverse 
transcribed using appropriate pyridoxal kinase primers in addition to house-keeping genes 
accordingly. 
The primer design was performed according to protocol, using “Nucleotide” library in” 
PubMed”, the search was conducted by encoded gene’s name “PDXK” with specifying the 
species as rats (Rattus norvegicus (PDXK). The selected mRNA was chosen and a sequence was 
picked. The entire gene sequence was copied and utilizing “BLAST” program to identify 
sequence similarities. The region that has the longest distance between two adjacent exons was 
chosen. The new sequence was pasted into http://frodo.wi.wi.mit.edu/ to get the following 
primers: 
 
Rattus norvegicus (PDXK): 
LEFT PRIMER         ctctccatccagagccatgt 
RIGHT PRIMER        cacagagttcacggcatcaa 
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  The sample preparation was carried out according to standard protocol, Trizol was added to 
tissues and tissues were homogenized in test tube, 200 µL of chloroform was added into 1 ml of 
homogenate in an Eppendorf tube, and total RNA extraction was performed according to 
protocol.  The reverse transcription reaction was carried out according to protocol, eleven µL of 
RNA extracted from previous step was added to 1µL of primer and dNTPs. After running 
samples in PCR for 5 minutes, buffer, DTT and reverse transcriptase enzyme to samples were 
added and ran it in PCR (Two steps reaction). These steps yielded the cDNAs. Two µL of cDNA 
resulted from previous step was mixed with SYBR green dye with buffer and primers specific to 
PDXK gene. Finally RT-PCR was run according to the protocol. The following instruments were 
used: Eppendorf master cycler gradient 5331 (PCR), Eppendorf 5424 microcentrifuge with 
knobs and Applied Bio systems 7900HT Fast Real Time PCR System. Decrease expression: The 
RT-PCR results in measuring the mRNA expression compared to house-keeping gene of choice 
(Actin) will show if there will be a reduction in amount of enzyme protein expressed. The 
method used for calculation is called Delta Delta Ct Method from manufacturer as previously 
described. 
 Pyridoxal kinase activity in the rat liver extract was also carried out as previously 
described. The concentration of P5P was determined after 1 hour reaction, which will be 
corresponding to the amount of protein needed for the reaction. The enzyme activity is defined as 
the concentration of P5P/mg protein in 1 hour at 37 °C.  
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6.3 RESULTS AND DISCUSSION 
The total protein assay was linear over the range of the concentration used with R2 
=0.999. Figure 30 All animal groups underwent surgery showed a significantly lower total 
protein content when compared with the animals in the control group. However, the total protein 
content of both the allograft group and the tacrolimus treated allograft group were significantly 
lower than the isograft graft group. The underlying reason for this finding needs further 
investigation. 
 
 
                                  Figure 30. Total protein calibration curve 
 
All Transplant rat groups total protein were compared using single factor ANOVA where 
all groups were significantly different from each other (p-value <0.05). All these liver extracts 
total protein content were corrected to liver weight.  The post hoc bonferoni correction with a p-
value =0.0125 for the all subgroup analysis. The post Hoc analysis confirmed a significant 
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difference between allogenic transplant groups and the control. Both allogenic transplant groups 
(Allogenic group and allogenic receiving tacrolimus group) were not different in total protein 
amount in the liver. The results are shown in Figure 31. 
 
 
Figure 31. Total protein content in different limb transplant rat groups (n=5), C: control, 
Iso: isograft, allo-tac: tacrolimus treated allogenic, allo: allogenic 
 
The mRNA expression in the livers of different rat groups was compared to controls and 
to each other. ANOVA comparison between groups was significant with p-value <0.05. The post 
Hoc analysis with Bonferroni correction (α/4) the allogenic rat groups were significantly lower 
than the control group. P-values were <0.0125 for allogenic group and for allogenic group 
treated with tacrolimus.  
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The lowest expression of pyridoxal kinase mRNA was in the allogenic transplant rat, 
which was significantly lower than the control group (p-value<0.0125). The other allogenic 
transplant group that received tacrolimus was also statistically significantly lower than control. 
The isograft group was not different from the control (p-value=0.22) .The effect on hepatic 
pyridoxal kinase following a different non-liver transplantation can be explained by the cascade 
of events that accompanied the rejection or the immunomodulation by elevated inflammatory 
markers. The results are shown in Figure 32. 
 
 
Figure 32. Pyridoxal kinase mRNA expression in different limb transplant rat groups 
(n=5), C: control, Iso: isograft, allo-tac: tacrolimus treated allogenic, allo: allogenic 
 
The overall total protein content in liver in allogenic group without tacrolimus was also 
statistically significant compared to control and that might indicate an effect of the 
transplantation on a distant organ like the liver function despite the fact it is not the transplanted 
organ and consequently affect the different enzymes expression and function in the body. The 
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mechanisms so far are not well identified, but can be attributed to elevated levels of cytokines 
status post transplantation that might have an effect on liver function and other metabolizing 
enzymes like pyridoxal kinase.  Also, the lower total liver  protein might be used as an early 
predictor of rejection or allograft failure , serum albumin was suggested as an independent 
predictor of poor outcomes in kidney transplant recipients however the clinical adoption of such 
an initiative need further support and evidence [119]. 
The pyridoxal kinase activity measured by the metabolically active form pyridoxal 5` 
phosphate concentration with rat liver extract after incubation for an hour. The measured 
concentration was normalized to the total protein content and was significantly less in the 
allogenic transplant group when compared to all other groups. The activity was notably lower 
than that of the control in the allogenic transplant rat group while there was no statistically 
significant difference in the activity between any other groups. The results are shown in Figure 
33. 
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 Figure 33. Average pyridoxal 5’phosphate concentration in different rat transplant livers 
extracts (n=5), C: control, Iso: isograft, allo-tac: tacrolimus treated allogenic, allo: allogenic 
 
Limitations: composite tissue allogenic transplantation provides an experimental model 
to study the effect of transplantation on other organs. The differences between CTA and small 
bowel transplantation is not known or even evaluated. However, it is novel and innovative to 
study the non-transplanted organ for it’s the global effect of inflammation/ transplantation on 
metabolic capacity of an organ like liver. The sample size was conveniently small rather 
adequate for the comparison purposes. Cytokines profiling in tissues and plasma might further 
explain these effects of the liver and other organs as well.  
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6.4 CONCLUSIONS 
Transplantation is a process where the transplanted organ is subjected to inflammatory 
processes like ischemia/ reperfusion and rejection, both of which involve release of cytokines. 
The effects of different cytokines on metabolic enzymes and/or transporters have been 
documented earlier. There were no studies on the effect of these inflammatory markers that 
accompanied transplantation or rejection on pyridoxal kinase activity.  
Transplant allogenic group that was not treated with tacrolimus showed the lowest level 
of pyridoxal kinase mRNA expression and the liver extract showed the lowest activity. Allogenic 
transplant group livers showed the lowest total protein content, which might explain the lower 
levels of expression. However the activity is normalized to total protein content and still the 
activity is significantly lower than all groups. The rejection may lead to down regulating various 
enzymes in the hepatocytes than the effect of either the surgery itself or the drugs given to 
prevent rejection like tacrolimus. The tacrolimus treated group as well as autogenic group   were 
also significantly lower in total protein compared to control group, similarly, the expression in 
allogenic groups were significantly different from control.  Tacrolimus as a treatment that 
prevented rejection did not interfere with pyridoxal kinase expression or the corresponding 
activity. 
In summary, the animal study with different transplant models highlighted the effect of 
transplantation on total liver protein and more specifically on pyridoxal kinase expression. The 
allogenic transplantation group who underwent rejection shortly had the lowest mRNA 
expression of pyridoxal kinase and that suggested lower metabolic rate during or following 
transplantation. However, the tacrolimus treated allogenic transplant group was not different 
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from the control or autogenic group which suggested that immunosuppression may restore the 
pyridoxal kinase functional capacity.   
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7.0  CONCLUSIONS 
7.1 INTRODUCTION 
Vitamin B6 deficiency is biochemically expressed as low levels of the bioactive 
metabolite, pyridoxal 5` phosphate (P5P). Vitamin B6 deficiency has been reported in several 
solid organ transplant recipients with the highest incidence being observed in small bowel 
transplant recipients. Nearly 96% of the small bowel transplant recipients have been reported to 
be deficient in vitamin B6. Clinically, the deficiency has many manifestations and symptoms that 
can exacerbate as neurological, hematological, as well as metabolic abnormalities. While limited 
systematic studies have been carried out to evaluate the nutritional status of the transplant 
recipients, no study to date has evaluated the potential mechanism(s) that might contribute to the 
observed high incidence of vitamin B6 deficiency in transplant patients. In theory, the nature of 
the transplantation procedure (trauma of the surgery), the immunogenicity of the transplanted 
organ, the inflammatory status of the transplant recipient, and the drug treatment protocols used 
in transplant recipients, might contribute to the observed vitamin deficiency in this population. In 
this study we evaluated potential mechanisms (increased degradation of P5P due to higher levels 
of alkaline phosphatases; or decreased formation of P5P due to decreased expression and activity 
of pyridoxal kinase) that may contribute to such observations  
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The majority of P5P is formed in the liver by pyridoxal kinase and in the blood it is 
associated primarily with erythrocytes and plasma albumin. P5P is degraded by alkaline 
phosphatase in to products that are further oxidized to the terminal urinary byproduct 4-
Pyridoxic acid (4-PA). Our studies in small bowel transplant patients documented that higher 
amount of 4-PA is excreted in these patients compared to normal healthy volunteers. The 
increased excretion was associated with higher plasma concentrations of alkaline phosphatase. 
Increased excretion can also be due to lower extent of binding of P5P to albumin, given that the 
plasma albumin concentrations in the small bowel transplant patients were lower than normal.   
 
Decreased formation of P5P as another possible mechanism was supported by several 
observations. Potential contribution of some of the medications used in transplant recipients was 
evaluated by computational approach. Mycophenolic acid and pantoprazole were identified as 
two potential candidates for further evaluation. Tacrolimus, a common immunosuppressive drugs 
was identified not likely to be an inhibitor based on computational studies. Further evaluation in 
cytosol and human hepatocytes indicated that tacrolimus has minimal effect overall on the 
expression and activity of pyridoxal kinase. Pro inflammatory cytokines, specifically TNF-α was 
observed to down regulate the expression and decrease the activity of pyridoxal kinase in human 
hepatocytes. The observation of increased pro-inflammatory cytokine levels in the serum of 
small bowel transplant patients is consistent with the lower levels P5P in this patient population.  
 
Finally, in a preclinical limb transplantation setting, we directly documented that the process of 
transplantation of an organ, that is not associated with the absorption, distribution or elimination 
of vitamin B6, it self down regulates the expression and activity of pyridoxal kinase.  
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 In Conclusion, the increased degradation of pyridoxal 5` phosphate due to non-drug related 
inflammatory processes (increased alkaline phosphatase, decreased serum albumin) in addition 
to down regulation of pyridoxal kinase due to elevated proinflammatory cytokines may explain 
the vitamin B6 deficiency observed in transplant patients.  
 
Summary  
Hypothesis 1: Plasma pyridoxal 5` phosphate concentrations will be decreased in 
transplant patients due to increased degradation mediated by elevated plasma alkaline 
phosphatase concentrations. 
   
 Increased urinary excretion of 4PA in small bowel transplant patients supports 
increased P5P degradation in this patient population. 
 Increased serum concentrations of alkaline phosphatase supports its potential 
contribution to increased degradation of P5P. 
 Both serum alkaline phosphatase and 4PA excretion appear to recover towards normal with 
time post transplantation.  
 
Hypothesis 2: Free fraction of pyridoxal 5` phosphate will be increased due to lower 
concentration of albumin in patients or due to displacement by other drugs that are also 
bound to albumin (Tacrolimus) and this will lead to increased clearance of P5P to 4-PA 
 Lower albumin level in transplant subjects is consistent with increased free fraction of P5P. 
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 Albumin concentrations tend to normalize with time post transplantation and this is 
consistent with reduced 4PA excretion with time post transplantation.  
  Tacrolimus did not alter in vitro binding of P5P and does not contribute to 
increased 4PA excretion in urine. 
 
Hypothesis 3: Plasma pyridoxal 5` phosphate concentration will be decreased in transplant 
patients due to decreased expression of pyridoxal kinase and/or direct inhibition of 
pyridoxal kinase involved in its formation by concurrent drugs administered. 
 
 Pyridoxal kinase activity was inhibited significantly but minimally by tacrolimus at 
concentration ≥10ng/ml in cytosol.  
 Pyridoxal kinase expression was inhibited by tacrolimus significantly but minimally 
at 20µg/ml in human hepatocytes 
 Chronic administration of tacrolimus at a concentration of 20 ng/ml significantly 
but minimally decreased the expression of pyridoxal kinase. 
  Based on in silico testing pantoprazole and MPA appear to be good candidate for 
inhibition of pyridoxal kinase activity. 
 
Hypothesis 4: Plasma P5P concentrations will be lower in transplant patients due to 
decreased expression or inhibition of pyridoxal kinase by increased cytokine levels 
The following cytokines were elevated post transplantation (IL-6, IL-8, IL-10, and TNF-α) 
during the early post-transplant study session.  Both IL-6 and TNF- α levels remained 
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elevated at the later post-transplant session. TNF- α significantly decreased the expression 
and activity of pyridoxal kinase in primary cultures of human hepatocytes.  
 
Hypothesis 5: The process of transplantation itself will elevate inflammatory markers and 
will decrease the expression and activity of pyridoxal kinase. 
 
 Livers from allogenic Transplant group not treated with tacrolimus showed 
the lowest level of pyridoxal kinase mRNA expression and lowest activity. 
 Livers from allogenic transplant group showed the lowest total protein 
content among all groups studied. 
 Livers from allogenic transplant group treated with tacrolimus were similar 
to these of autogenic group in expression and activity of pyridoxal kinase. 
 
 
Strengths of the proposed study: 
 
1. This study performed a mechanistic analysis of the observed vitamin 
B6 deficiency. 
2. It utilized computational approach, in vitro testing and in vivo animal 
and clinical studies to identify potential mechanisms. 
3. Identified the potential contribution of inflammatory status on vitamin 
B6 deficiency. 
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Limitations of the current work: The project conducted has certain limitations that 
must be addressed in future studies.  
 
1. The clinical study was performed in a small number of patients. This is due to the nature 
of the surgical procedure involved and the limited number of patients undergoing small 
bowel transplantation at any given center. This issue can be overcome in the future by 
performing multicenter collaborative studies. 
2. While the vitamin B6 deficiency has been documented in small bowel transplant patients 
already, plasma concentrations of P5P were not directly measured in the patients who 
participated in this study at the time of the study. This can readily be addressed in future 
studies 
3. Direct involvement of alkaline phosphatase in the degradation of P5P has been reported 
in the literature. In future studies the degradation kinetics of P5P can directly be 
measured in the patient population studied. 
4. Plasma albumin concentration was used as an indirect method of estimating free fraction 
of P5P in this study. Given that P5P is bound to albumin and to red blood cells, future 
studies should also directly measure plasma protein binding and red blood cell binding of 
P5P. 
5. The computational approach identified a few of the drugs used in transplant patients as 
potential inhibitors of pyridoxal kinase. These drugs can be directly tested as inhibitors of 
pyridoxal kinase using liver cytosol.  
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6. Additional drugs used by transplant patients can be evaluated for their effect on pyridoxal 
kinase using the computational approach developed in this work.  
7. The effect of tacrolimus and cytokines on the expression and activity of pyridoxal kinase 
was evaluated in vitro in this study. Data on the protein content of pyridoxal kinase will 
add additional dimension to the observations and facilitate data interpretation.  
8. While various cytokines were measured in the clinical study and previous animal studies 
had documented increased cytokine levels in the animal model used, a direct 
measurement of the cytokine levels and expression was not performed in the rats used in 
the current study. This information will provide additional support for the involvement of 
cytokines in mediating the low levels of P5P. 
9. Multicenter studies focusing on nutritional status of transplant patients in general and 
vitamin B6 levels in particular should also be carried out.  
 
7.2 FUTURE DIRECTIONS  
1. There is great interest in further investigations of different micronutrient after organ 
transplantation. In particular, a systematic evaluation of the vitamin status in organ 
transplantation deserves more attention.  
2. The magnitude of nutritional deficiency is expected to vary with the organ transplanted. 
Multicenter studies of patients after small bowel transplant should be conducted. 
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3.  Further investigation on the correlation between the results of computational approach 
and direct activity measurements of pyridoxal kinase should be conducted  
4. There could be additive or synergistic effect of tacrolimus and cytokines that has not been 
analyzed in this study. So the future study should measure the impact of tacrolimus along 
with cytokines 
5.  Given that one of the most common side effects of tacrolimus is neurotoxicity, and that 
vitamin B6 deficiency can also contribute to neurotoxicity, the impact of vitamin B6 
deficiency in exacerbating the neurotoxicity of tacrolimus must be investigated.  
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APPENDIX A 
[LIVER HOMOGENATE PREPARATION] 
1. Work on ice during all steps.  
2. Remove the liver from the animal and put it in a beaker containing homogenization buffer.  
3. Remove the buffer to remove excess blood.  
4. Blot liver lightly and weigh.  
5. Cut the liver into small pieces with scissor. 
6. Liver samples (5 gm) were placed in homogenization buffer (50 mM Tris HCl buffer, 1.0 % KCl 
and 1 mM EDTA, pH 7.4, and 3.0 ml per gm liver) and homogenized using an electrical 
homogenizer and homogenizing up and down 11 times, keeping vessel on ice. 
7. The homogenizer should be moved for 5 sec intervals. 
8. Centrifuge 20 min at 10,000 g or 10,000 rpm at 4 ºC depending on rotor speed. 
9. Pipette supernatant from previous step into clean tubes.  
10. Freeze and store at -80ºC. 
 
 
 
 148 
 
Buffers Required: 
Buffer:  0.05M Tris HCl  or  7.88 g/l 
  1.15% KCl   or 11.5 g/l 
  1mM EDTA$  or 0.3722 g/l 
  pH = 7.4 adjusted by NaOH or Glacial Acetic Acid (if Tris Base is used). 
  1/1000 BHT (5 mg/ml Stock) 
   1/1000 PMSF (40mg/ml Stock) 
$ - EDTA = ethylene diamine tetraacetic acid 
* - BHT = Butylated Hydroxytoluene is diluted as 1000 X stock (5mg/ml) in Ethanol. 
Antioxidant that terminates auto oxidation 
** - PMSF = Phenylmethylsulfonyl fluoride is diluted as 1000 X stock (40mg/ml) in 
Ethanol. Serine protease inhibitor.   
 
Note: Average protein content in human liver is 32 mg/ml. 
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APPENDIX B 
[RT-PCR PROTOCOLS] 
Day1: Extraction of mRNA and reverse transcription 
1. Remove culture medium from the hepatocyte 6-well plate 
2. Add 1 ml Trizol into each well, mix and incubate at room temperature for 5 minutes.  
3. Transfer the solution into eppendorf tubes, add 200 µL chloroform to each tube, 
shake with hands (don’t vortex) for 15 seconds, incubate at RT for 2-3 minutes until 
the two layers separated. Centrifuge at 4⁰C, 12000 rpm for 15 minutes 
4. Transfer the colorless supernatant to another tube. (Take out the supernatant from top 
to bottom, slowly pipet up. Usually 450 µL solution can be taken out the 50 µL 
supernatant is left. Some protein may be between the layers, don’t take the protein) 
Add the same volume of isopropanol (450µL), and then add 10 mg/ml glycogen 1µL 
(the amount of mRNA from cell sample is very small so we add the beads which bind 
to RNA and make it visible). Shake with hands. Centrifuge at 4⁰C, 12000 rpm for 15 
minutes. 
5. Pour out the supernatant. Add 75% Alcohol (~800 µL to wash), shake few times. 
Centrifuge at 4⁰C, 12000 rpm for 15 minutes. 
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6. Remove the supernatant (pour out, be gentle), centrifuge again at 4⁰C, 12000 rpm for 
5min, pipet to remove residual supernatant. Air-dry 5-10 min until transparent. 
7. Add 15 µL water (auto-claved ultra-pure water, dispose the whole tube after use) to 
each tube. Mix and transfer 11µL sample to another tube (0.3 ml small tubes in line) 
8. Add 1µL dNTP and 1µL Oligo dT (12-18t) primer (for binding to poly-A tail) to each 
sample. (In this step, make master mixture of dNTP and Oligo dT is helpful to 
decrease variation) 
9. Incubate for 5 min at 55-60 ⁰C in the PCR machine (program: AB) and then put them 
on ice immediately, wait for at least 2 minutes. (This step is to let AAA bind to TTT. 
Poly-A might be separated with Oligo dT if temperature drops down slowly.) 
10. 5*FS (first strand cDNA) buffer 4 µL, 0.1 M DTT 2.5 µL (proteinase inhibitor, 
prevent degradation of reverse transcriptase), superscript III 0.5 µL (reverse 
transcriptase), and then add 7 µL mixture to each tube. ( total volume of each sample 
11+1+1+7=20µL make master mixture for sample number+1) 
11. RT (reverse transcription): 1.5 hr (program: A9). Continue with Real Time PCR or 
store the samples in -20⁰C 
 
Day2: Real time PCR 
1. Dilute the samples 4-folds with water 
2. 20 µL  SyBr Green system: (2* master mix 10 µL, water 7 µL, primer 1µL)*(sample 
number +1), + sample 2µL. Master mix contains enzyme, dNTP, buffer and SyBr 
green. Be careful: never touch the bottom or upper side of the plate with finger. 
3. Cover the film, press each edge with flat plate and let it attach tightly. 
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4. Centrifuge for twice, for the first time, centrifuge briefly and shake by tapping the 
edges and centrifuge for 5 min, 2500 rpm. 
5. Put the plate in Real-time PCR machine. Set up: the name, volume of the sample and 
location, save. Choose the “dissociation curve” 
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